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Abstract
Although cancer survival rates have significantly improved over the past few
decades, the improvements are primarily due to early diagnosis and inhibiting cancer
growth. Limited progress has been made in the treatment of cancer metastasis, which
contributes to 90% of cancer related deaths, and therapeutic agents targeting the various
aspects of metastasis are lacking. One potential approach is to utilize small
pharmacological compounds to inhibit tumour cell motility, as a strategy against tumour
cell migration, invasion, and metastasis. The acetylenic tricyclic bis-(cyano enone), TBE31, has been shown to be a promising chemopreventative compound. However, its effects
on cell migration are unknown. This thesis focuses on deciphering the molecular
mechanisms TBE-31 utilizes to inhibit cell migration. I demonstrated that TBE-31 binds
with cysteine 374 of actin, inhibits actin polymerization and stress fiber formation. These
findings were applied to a model of epithelial-to-mesenchymal transition, a precursor
event to metastasis, where I determined TBE-31 was able to inhibit the crucial
rearrangement of cortical actin to form actin stress fibers, which prime tumour cells for
migration. In addition to the actin cytoskeleton, I demonstrated that TBE-31 alters
microtubule dynamics and organization. Microtubule-dependent trafficking was also
shown to be disrupted by TBE-31, and the localization of the polarity proteins Rac1,
IQGAP and Tiam1 were altered from the leading edge of migrating cells. Lastly, TBE-31
was shown to inhibit Rat2 and NIH3T3 fibroblast as well as H1299 non-small cell lung
cancer tumour cell migration. Taken together, my work provides novel insights on the
underlying mechanisms by which TBE-31 utilizes to inhibit cell migration and provide
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important knowledge for developing therapeutic compounds that target tumour cell
motility in metastasis.
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Introduction
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1

Introduction

1.1 Cancer Metastasis
Cancer arises from cells that have undergone multiple genetic mutations that lead
to the loss of normal cell behaviour

1,2

. These mutations initially result in uncontrolled

growth and proliferation. As the malignant cells continue to gain genetic mutations, a
portion of these cells will gain the ability to migrate and invade adjacent tissue, and
eventually disseminate to distant organs where they may establish new tumour colonies.
These colonies are known as metastases, and are responsible for over 90% of human
cancer related deaths

3-6

. Cell migration is a key process in regulating metastasis, and to

date effective drugs targeting metastasis are lacking 7-9.

1.2 Cell Migration: an Overview
Cell migration is a broad term used to describe the process that involves the
translocation of cells from one location to another. This may occur in inert environments
such as in soil, or on glass or plastic as is commonly seen in in vitro experiments, or
within complex multicellular organisms

10-12

. Cells migrate in response to stimuli from

their environment and this plays an essential role in many major physiological processes
such as embryogenesis, growth, development, immune response and wound healing 10-12.
However, abnormal cell migration can contribute to pathological conditions, such as
autoimmune diseases, chronic inflammation and cancer 10-16.
Cell migration can be broken down into a set of component processes, which
include front/rear polarization, protrusion, adhesion, translocation of the cell body, and

3

retraction of the rear (Figure 1.1). These processes are orchestrated by a network of both
intracellular and extracellular signaling molecules and the cytoskeleton

10-12

. Although it

is helpful to think of these as separate, individual processes, in actual fact they flow
seamlessly from one another or overlap each other. We begin with a cursory overview of
the entire process before examining the major cellular components in more detail.

1.2.1 Polarization
Cell polarization is often thought of as the initial step in cell migration.
Polarization in cell migration refers to the tendency of a migrating cell to have a distinct
front or leading edge, and a rear or lagging end. This is often stimulated and reinforced
by environmental cues. These cues can be chemotactic (induced by chemoattractants or
morphogens), haptotactic (from varying concentrations of substrate), mechanotactic
(breakdown of cell-cell contacts), electrotactic (induced by electric fields), durotactic
(due to differences in pliability), or a combination of these. The microtubule network
rearranges, polarity proteins are delivered to the leading edge, and actin polymerization
begins 10-12,17,18.

1.2.2 Protrusion
Protrusions are the de novo formation of extensions in the plasma membrane in
the direction of migration. The protrusion is primarily driven by the local polymerization
of actin. Large broad, fan-like protrusions are formed by branched actin polymerization
called lamellipodia or alternatively thin spike-like protrusions can be generated by

4

Figure 1.1 An overview of cell migration
Cell migration begins with i) polarization of the cytoskeleton towards the direction of
migration. The polarity proteins initiate actin polymerization to generate ii) protrusions
in the plasma membrane known as lamellipodia. New focal iii) adhesions underneath the
lamellipodia adhere the membrane to the substratum. Meanwhile the focal adhesions at
the rear disassemble and the iv) cell body translocates and the rear retracts.

5

6

parallel bundles of actin called filopodia. These two forms of protrusions are thought to
have different roles, with the former contributing primarily to forward movement and
traction, and the latter providing mechanosensory and exploratory functions 10-12,19.

1.2.3 Adhesion
Focal adhesions are mainly composed of integrin receptors, a large superfamily of
heterodimeric receptors, which form specialized attachments sites wherein cells make
contacts with the extracellular matrix (ECM)

20

. They are dynamic structures that form

underneath the cell protrusions to provide traction to the substratum. They grow and
shrink in size due to the recruitment and disassembly of proteins in response to
mechanical forces. Focal adhesions are able to link the cytoskeletal network to the ECM,
allowing cells to respond to the external environment through a feedback loop of, “insideoutside-inside,”

signaling.

Cellular

contractility

generated

by

the

actomyosin

cytoskeleton is transmitted to the ECM as traction forces by focal adhesions, and cells are
also able to sense the local extracellular environment via focal adhesions 10-12,20,21.

1.2.4 Cell body translocation and retraction of the rear
Cell body translocation and retraction of the rear are the least well-understood
processes in cell migration. Cell body translocation involves the coordinated contraction
of the actomyosin cytoskeleton, and the microtubule network and motor proteins such as
dynein help translocate the nucleus and other organelles. Meanwhile at the rear, mature
focal adhesions are disassembled and contraction of the actomyosin cytoskeleton leads to
retraction 10-12,22.
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As the above steps—polarization, protrusion, adhesion, cell body translocation,
and retraction of the rear—continue to occur in a cyclical fashion, the cell will translocate
forwards.

1.3 Cell Migration: the role of Rho GTPases, actin and
microtubules
Cell migration is a complex, multi-step process, involving careful orchestration
and coordination between signaling molecules and the cytoskeleton. Polarity proteins
establish and maintain a leading edge for proper directional movement, and help regulate
the cytoskeleton. The actin cytoskeleton provides force for protrusion, and tension for
retraction. While the microtubules establish a network for organelle translocation and
protein delivery 10-12. These three components, their regulation, and their contributions to
cell migration will be covered in greater detail below.

1.3.1 Polarization and the Rho GTPases
Rho GTPases belong to the Ras superfamily of small GTPases and are highly
conserved throughout eukaryotes. To date, over 20 Rho GTPases have been identified,
and it is thought that each one acts as a molecular switch to control distinct biochemical
pathways

23-25

. However only Rho (three isoforms, RhoA, RhoB, and RhoC), Rac (three

isoforms, Rac1, Rac2, and Rac3) and Cdc42 have been studied extensively. Like all
regulatory GTPases, these proteins are found in an inactive GDP-bound conformation,
and in an active GTP-bound conformation. The interconversion between the two is
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regulated by three types of regulatory proteins. Guanine nucleotide exchange factors
(GEFs) activate GTPases by catalyzing the exchange of GDP for GTP, whereas GTPaseactivating proteins (GAPs) increase the intrinsic GTP hydrolysis rate, thereby
inactivating it (Figure 1.2A)

23-25

. Guanine nucleotide dissociation inhibitors (GDIs)

sequester the GDP-bound form of some GTPases in the cytosol, and prevent them from
localizing to the membrane or being activated by GEFs

23-25

. Rho GTPases can be

activated directly or indirectly by various cell-surface receptors, including integrins,
cadherins, cytokine receptors, receptor tyrosine kinases and G protein-coupled receptors
26

. In the active GTP-bound conformation, Rho GTPases can interact with a range of

effector proteins including kinases, actin regulators and adaptor proteins, leading to
changes in cell behaviour. The spatiotemporal regulation of each Rho GTPase is
therefore important to determine the outcome of its activity 23-25.
Cell migration is an inherently polarized process, with the molecular processes at
the front different from those at the rear. Whether cell polarization is induced by a
chemical gradient of soluble or membrane-bound chemoattractants, or by the localized
activation of integrins, the recruitment and activation of the Rho GTPases, Cdc42 and
Rac, at the leading edge are major events necessary for triggering cell polarity (Figure
1.2B) 10-12,23-25,27. The major targets for Rac and Cdc42 that mediate actin polymerization
in protrusions are the Wiskott–Aldrich syndrome protein (WASP)/WASP-family
verprolin-homologous protein (WAVE) family of actin related proteins 2 and 3 (Arp2/3)
complex activators. Rac1 stimulates lamellipodial extensions by activating WAVE
proteins, while Cdc42 binds to WASP proteins to stimulate Arp2/3. Cdc42 also affects
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Figure 1.2 Rho GTPases and cell migration
A) Rho GTPases can exist in an active (GTP-bound) or an inactive (GDP-bound)
confirmation. In the active state, they interact with target (effector) proteins to induce a
cellular response. Most Rho GTPases have an intrinsic ability to hydrolyze the GTP to
GDP and inorganic phosphate (Pi), but it is also promoted by Rho GTPase-activating
proteins (GAPs). The exchange of GDP for GTP is promoted by Rho guanine nucleotide
exchange factors (GEFs). In addition, when in the GDP-bound state, the Rho GTPases
can interact with Rho GDP dissociation inhibitor (GDI), which sequester the complex
and prevent reactivation.
B) During cell migration, external signals from the environment (for e.g. interaction with
the ECM, or soluble signals) activate Cdc42, Rac1 and RhoA to establish front-rear
polarity. Cdc42 binds to Par6, which activates aPKC. This promotes the local
phosphorylation and inhibition of GSK3, leading to rearrangements of the microtubule
network through microtubule-associated proteins (MAPs). Cdc42 and Rac1 activate
WASP and WAVE respectively, which in turn promotes branched actin polymerization
through Arp2/3 and promote lamellipodia formation. Cdc42 also acts on formin to
promote stress fiber formation and filopodia at the leading edge. Similarly, RhoA
activated formin, myosin II and ROCK to promote stress fiber formation and retraction at
the rear.
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polarity by localizing the microtubule-organizing center (MTOC) and Golgi apparatus in
front of the nucleus, to orient the two towards the leading edge. This aids in the
microtubule-mediated delivery of Golgi-derived vesicles to the leading edge, providing
membrane and associated proteins for protrusion

1-3,9-11,13

.These processes will be

covered in greater detail in the following actin and microtubule descriptions.

1.3.2 The Actin Cytoskeleton
1.3.2.1

Structure

Actin is the most abundant protein in most eukaryotic cells 28, and is expressed in
three main isoforms, α, β, and γ. There are three α-isoforms found in skeletal, cardiac and
smooth muscles, while β- and γ- isoforms are expressed in non-muscle and muscle cells.
The actin structure is highly conserved and the isoforms only differ by a few amino acids
28,29

. Actin is found both in globular monomeric (G-actin) or polymeric filamentous (F-

actin) forms. The 375 amino acid, 42 kDa protein, folds into two major α/β domains, also
often respectively referred to as the outer and inner domains due to their locations in
filamentous actin, or the small and large domains due to their apparent size difference
observed by electron microscopy. Each domain can be further divided into two
subdomains for a total of four domains 28,30. The polypeptide chain passes twice through
the two major domains at residue Lys336 and at linker helix Gln137-Ser145, which
functions as a hinge between these two domains. As a result, two clefts between the
domains are formed. The upper cleft binds nucleotides and associated divalent cations
(i.e. Mg2+), which form another important linkage between the two major domains. The
lower cleft contains primarily hydrophobic residues and is important in mediating
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longitudinal contacts between actin subunits in the filament. In addition, this hydrophobic
cleft is the major binding site for most actin-binding proteins, and small molecules, and is
thus often called the target binding cleft 28,31. The actin monomers polymerize to form the
actin filaments, which are constructed with two chains of actin that turn gradually around
each other to form a two-chained long helix 28.

1.3.2.2

Actin Polymerization

The first step in actin polymerization is nucleation, which is defined as the
formation of a stable multimer of actin monomers. This occurs slowly, and is the ratelimitimg step in polymerization due to the relative instability of actin dimer intermediates
and the activity of actin monomer sequestering proteins that suppress spontaneous
nucleation in cells 32. However, once a nucleus is formed, actin polymerization proceeds
quickly at the barbed fast growing plus end, and more slowly at the pointed minus end.
The ATPase activity of actin increases upon incorporation into the filament, and causes
the spontaneous hydrolysis of the bound ATP to ADP. This destabilizes the filament and
the ADP-actin dissociates and undergoes nucleotide exchange to revert back to ATPactin. This in turn provides more actin monomers for polymerization at the positive end.
The constant recycling of actin results in actin treadmilling (Figure 1.3A) 32-34.
The rates of nucleation and treadmilling of pure actin are far too slow to account
for the rates of cell migration, and a number of actin binding proteins are responsible for
facilitating nucleation and promote elongation 34. Filament nucleators bear little overall
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Figure 1.3 The actin cytoskeleton and cell migration
A) Actin treadmilling. i) Formation of actin oligomers are unfavourable. ii) Once an actin
nucleus is formed, the association of monomers proceeds quickly. The plus (+) end grows
much faster than the minus (-) end. iii) Hydrolysis of ATP and the dissociation of
phosphate destabilizes the actin and causes depolymerization. Dissociated ADP-actin
undergoes nucleotide exchange, and the resulting ATP-actin recycles back to the plus
end. iv) Rates of treadmilling are greatly increased by the actin depolymerizing factor
(ADF)/Cofilin family and Profilin. ADF/Cofilin facilitate the depolymerization of ADPactin, and Profilin facilitates nucleotide exchange of ADP-actin to ATP-actin.
B) Fascin bundles actin filaments to produce actin stress fibers.
C) When active, the actin-related protein 2/3 (Arp2/3) complex binds to the side of preexisting actin filaments to provide nucleation sites for actin, which results in a branched
array of actin filaments.
D) At the leading edge, stress fibers form spike-like protrusions in the plasma membrane
known as filopodia, and the branched actin forms a broad fan-like protrusion of plasma
membrane called the lamellipodia. Stress fibers are also present in the cell body and aid
in retraction of the rear.
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resemblance to one another, but all include the WASP-homology 2 (WH2) domain for
interacting with actin. Known nucleators include Arp2/3 complex and its large family of
nucleation promoting factors, Spire, CObl, VopL/VOpF, TARP and Lmod

28,34

.

Elongation factors also include a wide variety of formins—which are modular proteins
characterized by the presence of two conserved domains, formin homology 1 and 2 (FH1
ad FH2), as well as Ena/VASP

28,34

. Actin depolymerizing factor (ADF) also known as

cofilin, can induce ADP-actin depolymerization at the minus end

35,36

, while profilin

facilitates the nucleotide exchange of ADP-actin to ATP 37. The combined effect of ADF
and profilin enhances the rate of actin treadmilling by 125-fold alone

34,38

. A number of

other actin binding proteins also help regulate the temporal and spatial organization of the
overall actin cytoskeleton. There are three main types of actin-based structures found
within the cell: filopodia, lamellipodia, and stress fibers (Figure 1.3D)39.

1.3.2.3

Branched Actin and the Lamellipodia

During cell migration, the localization of Rac1 and Cdc42 activate the family of
WASP proteins, which includes the ubiquitous neural-Wasp (N-WASP), and suppressor
of cAMP receptor (SCAR)/WAVE isoforms 1, 2 and 3. These proteins in turn activate
Arp2/3. Arp2/3 is a complex of seven conserved subunits including the two actin related
proteins Arp2 and Arp3, and ARPC1, ARPC2, ARPC3, ARPC4 and ARPC5

34,40

. The

Arp2/3 activators help bring actin monomers close in proximity to the Arp2/3 complex,
once incorporated into an actin filament the complex provides a new nucleation point for
a daughter filament, which elongates at 70 degrees from the mother filament, thus
forming a branched array of actin filaments (Figure 1.3C) 40,41. During cell migration, this
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branched actin network forms the basis of the lamellipodia, the broad fan-like plasma
membrane projection that provides the primary form of forward locomotion 42.

1.3.2.4

Unbranched Actin; Filopodia and Stress Fibers

In contrast to branched actin, unbranched actin (also known as linear, or
processive actin) assembly contribute to creating actin structures such as filopodia, stress
fibers and actin arcs 39. Cofilin can sever existing actin filaments to provide more barbed
ends to provide sites for actin polymerization and Fascin can bundle actin filaments to
promote the formation of filopodia—the spike-like projections that function as
mechanosensory, and exploratory devices

35,36,43

. RhoA directly promotes stress fiber

assembly through its effectors, RhoA-associated protein kinase (ROCK) and the formin
mDia1 (mammalian Dia1; also known as DIAPH1 and DRF1). mDia1 promotes the
polymerization of long parallel actin filaments, whereas ROCK inhibits cofilin through
activation of LIM domain kinase 1 (LIMK1), ensuring that the forming actin filaments do
not get severed

39

. Stress fibers provide structure, and during cell migration, these actin

stress fibres are found to associate with focal adhesions, and help provide a contractile
force to retract the lagging end of the cell (Figure 1.3D) 22,39,44,45. Actin arcs are similar to
actin stress fibers in that they also provide structure, but do not directly attach to focal
adhesions, and display a periodic α-actinin-myosin pattern which contribute to their arc
structure and give them the ability to contract 39,46.

1.3.3 The Microtubule Network
Microtubules (MTs) are noncovalent polymers of the protein tubulin found in all
dividing eukaryotic cells and in nearly all differentiated cell types. During cell division, a
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large dynamic array of MTs called the mitotic spindle facilitates the physical separation
of chromosomes and serves to orient the plane of cleavage. In non-dividing cells, MTs
organize the cytoplasm, position the nucleus and organelles, and serve as the primary
structural components of the flagella and cilia

47,48

. During cell migration MTs help

establish and maintain the spatial and temporal coordination of migratory signals and
events 27,47,49.

1.3.3.1

Microtubule structure and dynamics

Microtubules are composed of heterodimers made up of α and β-tubulin
monomers, which are approximately 50% identical to each other at the amino acid level
and have a molecular mass of approximately 50 kDa 47. These heterodimers are aligned
in a polar head-to-tail fashion to form protofilaments and they associate laterally to form
a 25 nm wide hollow cylindrical microtubule (Figure 1.4A, B and C). The heterodimers
associate in the same direction and generate a polarized filament with a distinctive minus
and plus end. In a cell, the minus end is anchored to the microtubule organizing center
(MTOC), while the plus end is free to associate with heterodimers to further elongate
47,50

. This polymerization is regulated by the hydrolysis of β-tubulin bound GTP (GTP

bound to α-tubulin is non-exchangeable and is never hydrolyzed), which occurs with a
delay after the tubulin heterodimer has been incorporated into the microtubule end. As a
result the newly formed microtubule tip contains a cap of GTP-tubulin, which helps
stabilize the structure, whereas the shaft of the microtubule is composed of GDP-tubulin
and is intrinsically less stable. In the presence of the cap a microtubule continues to grow,
and a loss of the cap leads to rapid microtubule shrinkage, termed catastrophe. For this
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Figure 1.4 The microtubule network and cell migration
A) Microtubules are composed of subunits of tubulin heterodimers formed from tightly
linked α- and β- tubulin monomers. The GTP molecule in the α-tubulin does not
hydrolyze to GDP, however the GTP molecule in β-tubulin does, which plays an
important role in filament dynamics.
B) The tubulin heterodimers align in a head-to-tail fashion to generate a polarized
protofilament.
C) The protofilaments associate laterally to form a 25 nm wide hollow cylindrical tube
known as a microtubule.
D) Microtubules are under a state of dynamic instability, characterized by polymerizing
(left) and depolymerizing microtubules (right). GTP-tubulin is incorporated at
polymerizing microtubule ends. The GTP is quickly hydrolyzed soon after
polymerization and phosphate is released, resulting in a GDP-tubulins shaft which is
intrinsically less stable than the GTP-tubulin cap. If a GTP-tubulin cap is not maintained
by incoming GTP-tubulin, the GDP-tubulin shaft depolymerizes (termed catastrophe). As
GTP-tubulin is replenished, the microtubule can transit back to polymerization (rescue).
The microtubules infrequently pause in a state, neither gaining nor losing tubulin subunits
and these tubulin heterodimers lie within a fully formed cylinder (bottom).
E) During cell migration, microtubules polarize, and maintain front-rear polarity by
coordinating specific cellular activities, including the transport of membrane vesicles to
the leading edge.
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reason, the microtubules are under a constant state of ebb and flow termed dynamic
instability, which is dependent on capping proteins and monomer concentration (Figure
1.4D). The nature of this instability helps the microtubule distribute in the cell during
cytoskeletal reorganization and undergo a, “search and capture,” process where the tip of
the microtubule shrinks and grows to explore the extracellular space until capturing an
organelle or microtubule associate protein 47,50.

1.3.3.2

Regulation and function in cell migration

Microtubules have long been implicated in cell migration, however the
mechanism of their involvement has remained unclear, and has even been considered
controversial at times. Most studies have concluded that microtubules play a positive role
in cell migration by regulating actin polymerization, transporting membrane vesicles to
the leading edge and/or facilitating the turnover of focal adhesions

49,51-53

. In general,

their greatest contribution is to maintain a polarized intracellular organizations and
correctly coordinate the position of specific cellular activities (Figure 1.4E) 27,49,54.
The local activation of Cdc42 is a crucial early event in cell migration leading to the
polarization of the microtubule network. Cdc42 can be activated by a wide variety of
polarity cues 55. In a scratch-induced migration assay, integrin engagement leads Src- and
Scrb-dependent activation of the protein βPIX, which in turn acts as Cdc42 specific GEF.
βPIX also contributes to the recruitment of Rac1, but is activated independently

55-57

.

Cellular redistribution of Cdc42 can also be initiated by soluble ligands acting as
membrane bound or membrane permeable chemoattractants. This mirrors the
establishment of an intracellular phosphoinositide gradient established by the activation
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of PI3K at the front and PTEN at the back

55,58,59

. Once activated, Cdc42 binds and

recruits Par6, and activates atypical protein kinase C (aPKC), which in turn promotes the
local phosphorylation and inactivation of GSK3 kinases. GSK3 is a constitutively active
serine/threonine kinase that regulates several +TIPs (microtubule plus-end tracking
proteins, a subclass of microtubule-associated proteins (MAPs)) and stabilizes a number
of MAPs. GSK3β can phosphorylate stathmin and help establish a gradient of stathmin
activity, which promotes microtubule growth at the leading edge and depolymerization at
the rear

55,60,61

. The inhibition of GSK3β at the leading edge also promotes the

recruitment of APC

55

. APC functions to help promote microtubule growth, but also

microtubule capture to the leading edge via the enhanced binding of IQGAP1 to Clip-170
12,55,62

.

1.4 Metastasis Cascade
Cell migration requires a complex orchestration of numerous proteins, and not
surprisingly, the dysregulation of any of these can lead to pathological diseases. In the
later stages of cancer, cell migration is exploited to allow tumour cells to spread to new
areas of the body in a process called metastasis. Metastasis is responsible for 90% of all
cancer related deaths, yet it remains the most poorly understood component of cancer
pathogenesis

3-6

. The basic steps of metastasis include the invasion of tumour cells into

the local tissue, intravasation into the lymph or blood system, dissemination,
extravasation, and colonization at distant organs (Figure 1.5)
covered in greater detail below.

6,63

. These steps will be
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Figure 1.5 The metastasis cascade
During metastasis progression, tumour cells acquire a more invasive phenotype through a
process termed epithelial-to-mesenchymal transition and exit their primary site of growth
and invade into the surrounding extracellular matrix (local invasion). When the cancer
cells reach the blood vessels, they can enter into the circulatory system (intravasation)
and distribute throughout the body (dissemination). Eventually the tumour cells will
arrest at a distant site, exit the circulation and invade the microenvironment of a foreign
tissue (extravasation). At the foreign site, the cancer cells must adapt to survive and
thrive (micrometastasis) before developing into full colonies (macrometastasis).
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1.4.1 Local Invasion and Epithelial-to-Mesenchymal Transition
Local invasion involves the entry of cancer cells that have resided within a wellconfined primary tumour into the surrounding tumour-associated stroma, and then into
the adjacent tissue parenchyma. The first barrier to invasion is the basement membrane, a
specialized extracellular matrix component that plays a vital role in organizing the
epithelial tissue by separating the epithelium from the stroma. Epithelial cells are highly
organized and form sheet-like layers that are held together by complexes such as tight
junctions, adherens junctions and desmosomes. In addition, they display apical-basal
polarity and are attached to the basement membrane. The precisely controlled tissue
architecture of normal epithelium keep the epithelial cells relatively immobile and serve
as an intrinsic barrier for tumour cell migration and invasion 14-16,63,64.
In order to overcome this and other obstacles for invasion, carcinoma cells may
co-opt a cell-biological program known as epithelial-to-mesenchymal transition (EMT)
(Figure 1.6) EMT is normally a critical process for healthy embryonic morphogenesis
where cells transition between epithelial and mesenchymal states in a highly plastic and
dynamic manner

65

. EMT programs are orchestrated by a set of pleiotropically acting

transcription factors (TFs)—including Slug, Snail, Twist, ZEB1, and ZEB2—which
trigger the entrance into a mesenchymal state by suppressing expression of epithelial
markers and inducing the expression of other markers associated with mesenchymal cells
14,63,65

. Cell-cell junctional proteins, like E-cadherin, which normally tethers epithelial

cells into sheets, are repressed, and N-cadherin, which is associated with mesenchymal
and migratory cells, are up-regulated

66

. The actin cytoskeleton rearranges from the cell

cortex to form actin stress fibers, and the overall apical-basal polarity is lost.
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Figure 1.6 Epithelial-to-mesenchymal transition
Epithelial-to-mesenchymal transition (EMT) is an important process during development,
but also marks an important event during tumour progression where cells become more
invasive and metastatic. Key events include the disruption of cell-cell junctional
complexes—such as tight junctions, adherens junctions and desmosomes—the loss of
apical-basal polarity and a restructuring of the actin cytoskeleton from cortical actin to
actin stress fibers. EMT also involves a shift in expression of epithelial markers (for e.g.,
E-cadherin and ZO-1) to cells that express mesenchymal markers such as N-cadherin and
vimentin. Cells that have undergone EMT display an enhanced migratory capacity and
increased invasive potential. The reverse process, mesenchymal-to-epithelial transition
(MET), may also occur.
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Consequently the precise architecture of normal epithelium is lost, and the cells begin to
exhibit multiple mesenchymal attributes, including heightened migratory and invasive
potential

14,63,65

. In addition, the Snail and ZEB factors induce the transcription of

metalloproteases that then degrade the basement membrane, enabling local cell invasion
14,65

.
After undergoing EMT and dissolving the basement membrane, carcinoma cells

migrate and invade into the stroma. Here the carcinoma cells encounter a variety of
tumour-associated stromal cells. The resultant composition of these associated stromal
cells is governed largely by the state of tumour progression. As the primary tumour
progression proceeds, the stroma becomes increasingly “reactive” which is to mean that it
acquires many of the characteristics associated with wound healing or chronic
inflammation

63,67

. Components of the tumour associated stroma can include fibroblasts,

myofibroblasts, endothelial cells, adipocytes, and various bone marrow-derived cells—
including mesenchymal stem cells, macrophages and other immune cells

63,68

. Crosstalk

between the tumour cells and the stroma enhance the aggressive behaviours of carcinoma
cells through various types of signaling. Therefore, there is a bi-directional interaction
that occurs between the tumour cells and the nearby stroma, the carcinoma stimulates the
formation of an inflamed stroma, and the stroma reciprocates enhancing the malignant
traits of the carcinoma, establishing a self-amplifying positive feedback loop 63,68,69.

1.4.2 Intravasation
Entry into the stroma provides opportunities for the tumour cells to access the
systemic circulation and disseminate to distant sites. Intravasation involves locally
migratory and invasive carcinoma cells entering the lumen of either the lymphatic or
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blood vessels

70

. Although intravasation into the lymphatic vessels occurs and is

important as a prognostic marker for cancer progression, intravasation into the
hematogenous circulation appears to represent the major mechanism by which metastatic
carcinoma cells disseminate, and this will be the primary focus in the following section
63,70

.
Intravasation requires cancer cells to cross the endothelium, a process that is

known as transendothelial migration (TEM). This can occur through paracellular TEM,
which involves the disruption of junctions between adjacent endothelial cells, which
allows the tumour cells to squeeze between them or transcellular TEM, which involves
the migration of cancer cells directly through the endothelial cell body

71-73

. Although

most studies have shown paracellular TEM in vitro, there is evidence suggesting they can
also use a transcellular route. Thus far, it is not clear which route is used by cancer in
vivo, or if the route is dependent on the vasculature or cancer type 73.
The major barrier for paracellular TEM is the presence of endothelial cell
junctions. In vitro it has been shown that cancer cells induce endothelial cell junction
opening by secreting various factors that activate signaling pathways in endothelial cells.
For example, the carcinoma cells or the tumour associated stroma, such as macrophages,
produce VEGF or TGFβ1, which can disrupt cell junctions based on VE-cadherin-βcatenin complexes and induce endothelial cell junction opening, thus facilitating cancer
cell TEM

73-75

. Other cancers may influence endothelial cell signaling by stimulating the

Rho GTPases to facilitate TEM by causing an increase in actomyosin contractility, and
stress fiber-mediated tension on adherens junctions, causing an opening

73,76

. Similarly,

endothelial RhoA is activated by lung cancer attachment to endothelial cells, which
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activate ROCKs, leading to increased stress fiber assembly, and tight-junction disruption,
to again facilitate cancer cell TEM 73,77.
Recent studies have provided some evidence to show that tumour cells may
migrate through the endothelial cell body instead of only through paracellular route.
During transcellular intravasation, the Ca2+-calmodulin complex in an endothelial cell
activates myosin light chain (MLC) kinase (MLCK) at the site of cancer cell attachment.
This induces a local phosphorylation of MLC and to actomyosin contraction, which leads
to rapid actin cytoskeletal and membrane remodelling which creates a transient pore-like
structure for the cancer cell to cross through the endothelial cell 73,76,77.
Intravasation can occur in blood vessels normally present near the primary
tumour, or through new blood vessels formed within the local microenvironment of the
tumour via the process of neoangiogenesis, which can be initiated by VEGF from the
carcinoma cells or tumour associated stroma. In contrast to the normal blood vessels, this
neovasculature generated in response to carcinoma cells is often described as tortuous,
prone to leakiness and in a state of continuous reconfiguration

63,78

. This weakened

vasculature is thought to facilitate tumour cell intravasation more easily.

1.4.3 Survival and dissemination through the circulation
Once the carcinoma cells have successfully intravasated into the lumen of blood
vessels, they can disseminate widely through the venous and arterial circulation.
However they must survive a variety of stresses in order to reach distant organs

63

. For

example, in the absence of integrin-dependent adhesion to the extracellular matrix,
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epithelial cells would normally undergo anoikis—a form of apoptosis triggered by the
loss of anchorage to substratum. Some of the signaling events in anoikis must be
repressed in the carcinoma cells79,80. In addition, the tumour cells must overcome the
damage incurred by the hemodynamic shear forces generated in the blood stream, and
predation by cells of the innate immune system 63.

1.4.4 Arrest and Extravasation
Once lodged in the microvasculature of distant organs, the circulating tumour may
form a microcolony that eventually causes the surrounding vessel to rupture, thereby
placing tumour cells in contact with the tissue parenchyma

63,81

. Alternatively, the

carcinoma cells may once again cross the endothelium by undergoing TEM as outlined
above. This may superficially resemble the steps of intravasation, but the process can in
fact be quite a bit more challenging. During extravasation the carcinoma cells no longer
have the co-opted tumour associated stroma to help provide signals, and the advantages
provided by the tortuous and leaky neovasculature at the intravasation site are absent 63,81.

1.4.5 Metastatic Colonization
Once extravasated the carcinoma cells must survive in a foreign microenvironment,
which can differ greatly from the site of the primary tumour formation. Differences may
include the types of stromal cells, extracellular matrix constituents, available growth
factors, cytokines, and even the microarchitecture of the tissue itself. For these reasons,
the disseminated cancer cells are, at least initially, poorly adapted to their new
surroundings. As a result, the tumour cells may suffer slow attrition over periods of

33

weeks and months, or persist as microcolonies in a state of long-term dormancy, neither
gaining nor losing overall cell number 63,82.

1.5 Targeting Metastasis
Despite the natural barriers, challenges, and the high rates of attrition that accompany
the steps of metastasis, overt metastases eventually do arise, and they almost invariably
represent the source of terminal disease

63,70

. The suppression of cancer metastasis is an

urgent therapeutic need, yet most existing drugs inhibit only cancer cell proliferation

7-9

.

Therefore identifying therapeutic agent(s) that may target any of the various cell
processes involved in metastasis will be crucial in reducing cancer mortality.

1.6 Synthetic Triterpenoids
1.6.1 Terpenes
Terpenes are a large and diverse class of organic compounds that function as
biosynthetic building blocks within nearly every living creature. Terpenes are derived
from units of isoprene, which has the molecular formula C5H8, therefore the basic
molecular formula for terpenes are multiples of (C5H8)n. This is known as the isoprene
rule or the C5 rule. Terpenes may be classified by the number of isoprene units in the
molecule, and a prefix in the name indicates the number of terpenes units needed to
assemble the molecule. One single isoprene unit or C5 (hermiterpenes), C10
(monoterpenes),

C15 (sesquiterpenes),

C20 (diterpenes), C25

(sesterpenes), C30

(triterpenes), C40 (tetraterpenes), >C40 (polyterpenes) 83-86. Strictly speaking terpenes are
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hydrocarbons, upon modification, oxidation, or addition of functional groups the terpene
is then known as a terpenoid, therefore a C30 triterpene with functional groups would be
called a triterpenoid. These terpenoids comprise the largest group of natural plant
products, with over 20,000 known members 86,87.

1.6.2 Triterpenoids and oleanolic acid
Triterpenoids are formed through the cyclization of the 30-carbon squalene, and
result in protostanes, lanostanes, holostanes, cycloartanes, dammaranes, euphanes,
tirucallanes, tetranortriterpenoids, quassinoids, lupanes, oleananes, friedelanes, ursanes,
hopanes, isomalabaricanes, and saponins. These triterpenoid carbon frameworks are
cyclized by members of the oxidosqualene cyclase family, which has expanded greatly in
plants 88.
Oleanolic acid and its isomer ursolic acid are triterpenoid compounds that exist
widely in plants, and have provided the basis of many traditional folk medicine due to
their anti-inflammatory and hepatoprotective abilities. Studies on oleanolic acid
confirmed that this triterpenoid does indeed have beneficial effects in numerous diseases,
including chemically-induced liver injuries and cancer

89-93

. However, these natural

triterpenoids were found to have poor bioavailability and relatively weak biological
activity, thus modification and synthetic versions of oleanolic acid have been made to
improve on these shortcomings 94,95.
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1.6.3 Synthetic Oleanane Triterpenoids
More than 300 derivatives of oleanolic acid have been made by the Gribble
laboratory (Dartmouth, USA, New Hampshire) and these molecules have been screened
for their abilities to inhibit the de novo synthesis of the inflammatory enzyme nitric-oxide
synthase (iNOS) 96,97. With the rationale being that inflammation is a causative factor for
the pathogenesis of many human diseases, including cancer. Of the initial candidate
screen, the 46th triterpenoid prepared (TP-46) in Gribble laboratory was identified as the
first, “hit,” in their iNOS assay. Subsequent refinement and modification lead to the
creation of TP-151 (“CDDO”) (2-cyano-3,12-dioxooleana- 1,9(11)-dien-28-oic acid),
which was over 10,000 fold more potent than TP-46, and approximately 400,000 times
more potent than oleanolic acid in their iNOS assay. Furthermore, it was found that by
modifying the C-28 site on CDDO and replacing it with different functional groups, more
potent synthetic oleanolic acid derivatives could be developed, two of which are CDDOImidazolide (CDDO-Im) and CDDO-Methyl ester (CDDO-Me) (Figure 1.7A)96,97.
As a group, these synthetic oleanane triterpenoids are multifunctional molecules
in cell culture assays. In the nanomolar-to-micromolar range, they have been shown to
suppress inflammation, activate cytoprotective pathways, induce differentiation, inhibit
proliferation and induce apoptosis 95,97-103.

1.7 Tricyclic Compounds
During the development of CDDO, structure-activity studies revealed that the 2cyano-1-en-3-one in ring A and a 9(11)-en-12-one in ring C are responsible for high
potency of CDDO. They reasoned that perhaps the entire oleanane skeleton might not be
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Figure 1.7 Synthetic oleanane triterpenoids and tricyclic compounds
A) The base structure of the synthetic oleanolic acid derivatives, CDDO, CDDO-Im, and
CDDO-Me. Highlighted in red are the enone moieties that contribute to the compounds
extreme potency compared to oleanolic acid.
B) The base structure for the acetylenic tricyclic bis-(cyano enone) compounds, TBE-31,
TBE-55 and TBE-56. Note the similarity in rings A and C when compared to the
synthetic oleanolic acid derivatives.
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necessary for its potency, and therefore focused their attention on generating a new class
of tricyclic compounds (tricyclic-bis-enone derivatives (TBEs)) which have the same A,
B, and C rings of CDDO

104,105

. In designing the tricyclic compounds, the medicinal

chemists have aimed to avoid some of the limitations of the synthetic oleanane
triterpenoids, in which only a single functional group at C-17 could be modified, and an
expensive 11 step synthesis required to convert oleanolic acid into CDDO. In contrast,
the TBEs could be entirely synthetic, and thus are not hindered by limited functional
groups or by steric hindrance and the new compounds may have more structural
diversity, better stability, enhanced pharmacokinetic and pharmacodynamics profiles
compared to the synthetic oleanane triterpenoids 104-106.
An early TBE-compound, TBE-9, was found to be nearly equivalent to CDDO in
potency, both in in vitro assays inhibiting activity against production of nitric oxide by
interferon-γ in mouse macrophages, and in in vivo studies using mouse peritoneal
inflammation induced by thioglycollate and interferon-γ.

97,104,105

. The design, synthesis

and biological evaluation of new TBE analogues was continued by the Gribble
laboratory. The acetylenic tricyclic bis-(cyano enone), TBE-31 [(±)-(4aα,8aα,10aβ)1,2,4a,6,8a,9,10,10a-octahydro-8a-ethynyl-1,1,4a-trimethyl-2,6-dioxophenanthrene-3,7dicarbonitrile], synthesized from cyclohexanone as a starting material, was again found to
be significantly more potent than CDDO (Figure 1.7B)106,107.

1.7.1.1

TBE-31 - The acetylenic tricyclic bis-(cyano enone)

Since the compounds design and conception in 2007, TBE-31 has become an
attractive candidate to be used as a lead compound. Different groups have assessed its
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ability to suppress chronic inflammation, act as a chemopreventative agent and even its
ability to serve as an anti-depressant 106.
Liby et al. in 2008, showed that nanomolar concentrations of TBE-31 were able
to suppress the induction of the inflammatory protein, iNOS, activate phase 2
cytoprotective enzymes in vitro and in vivo, block cell proliferation, and induce
differentiation of leukemia cells. When TBE-31 was orally administrated to rats, it
significantly reduced formation of aflatoxin-DNA adducts, and decreased the size and
number of aflatoxin-DNA preneoplastic hepatic lesions in rats by >90%. This work also
suggested TBE-31 may interact with DTT and thus proteins that contain reactive cysteine
residues, such as Keap1 108.
The Keap1/Nrf2/ARE pathway regulates the ability of eukaryotic organisms to
adapt and survive under various conditions of oxidative, electrophilic, and inflammatory
stress by signaling the expression of a network of more than 100 genes, many of which
encode for cytoprotective (“phase 2”) proteins. Under basal conditions, this pathway does
not operate at its maximal capacity, but can be induced by a wide variety of different
classes of small molecules. One universal property of these inducers is their capacity to
modify sulfhydryl groups by alkylation, oxidoreduction or disulfide formation

109-111

.

Much of the work by Dinkova-Kostova and her and her group has focused on this
pathway as a target for TBE-31. They demonstrated spectroscopically that both of the
cyano enone functional groups of TBE-31 react with Keap1 and activate transcription of
cytoprotective genes. By designing monocyclic compounds resembling fragmented rings
A or C of TBE-31 (Figure 1.7B), they were able to demonstrate that ring C had a greater
contribution as a Michael acceptor (i.e. greater ability to react with cysteines). Although,
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most importantly, the presence of both rings held together in the configuration of TBE-31
resulted in exceptionally high inducer potency towards the Keap1/Nrf2/ARE pathway 109.
Further studies focused on in vivo applications of TBE-31 and the
Keap1/Nrf2/ARE pathway. Long-term (five days per week for four weeks) topical
applications of small (200 nM) quantities of TBE-31 were found to cause robust systemic
induction of the Keap1/Nrf2/ARE pathway and decrease 6-ithoguanine nucleotide—
which is a metabolite of azathioprine, a highly effective anti-inflammatory and
immunosuppressive agent used in organ transplantation and autoimmune disease, but
which profoundly increases the risk for development of unusually aggressive cutaneous
squamous cell carcinoma—incorporation in DNA of skin, blood, and liver of
azathioprine-treated mice, indicating extraordinary bioavailability and efficacy. In
addition, TBE-31 at nanomolar concentrations protected cells that do contain 6ithoguanine in their genomic DNA against oxidative stress caused by UVA radiation
through the induction of the Keap1/Nrf2/ARE pathway. Thus, TBE-31 lowers two of the
risk factors that contribute to the development of skin carcinogenesis associated with
thiopurine therapies

112

. This was confirmed in further experiments where the dosage of

TBE-31 was also optimized. Topical TBE-31 (40 nmol/mouse, 2 days a week) was
administered to mice while simultaneously administering azathioprine (1mg/kg/d in the
drinking water) 2 weeks before starting an irradiation schedule, which consisted of
chronic suberythemal solar simulated UV radiation (comprised of 2 J/cm2 UVA and 90 m
J/cm2 UVB). After biweekly exposures for 15 weeks, irradiation was discontinued and
tumour development was evaluated during the subsequent 16 weeks. TBE-31 was
administered throughout these 31 weeks. The tumour incidences were not significantly
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different between the control and the TBE-31 treated groups, but tumour multiplicity
(tumour number) and tumour volume were all significantly lower. With the control group
having 9.5 tumours per mouse with an overall average volume of 225 mm3 per mouse,
compared to 5.3 tumours with an overall average volume of 41.9 mm3 per mouse for the
TBE-31-treated group

113

. In addition, in similar experiments the topical application of

TBE-31 was shown to reduce the upregulation of 3 important inflammatory markers, IL6,
IL1β and cyclooxygenase-2 by 55-, 24-, and 30% respectively, in the skin of UV
radiation-induced inflammation in mice. This protective effect was largely absent in
Nrf2-KO mice

113

. Overall, Dinkova-Kostova and her group demonstrate that TBE-31

effectively activate the Keap1/Nrf2/ARE pathway, reduce inflammation and reduce
tumour burden.
Other studies have explored TBE-31 and the Keap1/Nrf2/ARE outside of a
chemopreventative context. Nrf2 activators have anti-depressant effects in animal models
of depression. One study showed TBE-31 was able to potentiate nerve growth factor
induced neurite outgrowth in PC12 cells in a concentration dependent manner. This effect
was lost in Nrf2 siRNA treated cells. Furthermore, oral administration of TBE-31 to mice
significantly attenuated an increase in serum levels of tumour necrosis factor-α (TNF-α)
after administration of lipopolysaccharide (LPS). Lastly, in their LPS induced model of
depression, they found TBE-31 to lower signs of depression in the tail suspension and
forced swimming tests used to assess behaviour in mice. Therefore, TBE-31 may also be
a potential therapeutic drug for inflammation-related depression

114

. Aside from the

Keap1/Nrf2/ARE pathway, TBE-31 has also been found to be able to upregulate Hsp70
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in an HSF1-dependent manner in mouse embryonic fibroblasts (MEFs), and this has been
shown to play a role in protection against peroxynitrite-induced cytotoxicity 115.
The success of TBE-31 has prompted medicinal chemists to continue refining the
process of generating TBE-31. Steps in the synthesis have been improved to increase the
efficiency and yield of TBE-31

116,117

. Moreover, a method for generating

13

C215N2-

labeled TBE-31 and use in liquid chromatography-mass spectrometry (LC-MS) has been
established, which will be useful for quantification of cell, tissue and plasma levels of
TBE-31

118

. Lastly, a biotin conjugated TBE-31 has been generated for use as a tool for

the isolation of protein targets of TBE-31 (Figure 1.7B)119.

1.8 CDDO-Im, CDDO-Me and cell migration
Much of the current literature on the class of synthetic oleanolic acid derivatives
and TBE-31 has been focused on their anti-inflammatory properties as outlined above.
Although this is important work and has shown their potential use as chemopreventative
agents through their anti-inflammatory properties, it has not address their effects on
metastasis. Studies in the Di Guglielmo lab have begun exploring other important
properties of these compounds, namely the cytoskeletal altering effects of the synthetic
oleanolic acid derivatives and their effects on cell migration—an important component of
metastasis. More specifically, CDDO-Im was found to alter microtubule dynamics by
disrupting the microtubule capping protein, Clip-170. Microtubule-dependent processes
were also altered, including the dispersal of EEA1-positive endosomes from the
perinuclear region of CDDO-Im treated cells. Furthermore, CDDO-Im disrupted the
localization of IQGAP1, PKCζ, Par6, and TGFβ receptors from the leading edge of
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migrating cells and inhibited TGFβ-dependent cell migration (Figure 1.8A top)120. In
addition, CDDO-Im and CDDO-Me were also found to associate with Arp3, a subunit of
the Arp2/3 complex, which is necessary for branched actin polymerization and the
formation of the lamellipodia in migrating cells. CDDO-Im and CDDO-Me were found
to inhibit Arp3 localization at the leading edge, abrogate cell polarity, and inhibit Arp2/3dependent branched actin polymerization (Figure 1.8A bottom)121. The effects of CDDOIm and CDDO-Me on the microtubule network, cell polarity and the actin cytoskeleton
are all believed to contribute to inhibiting cell migration, thus making the synthetic
triterpenoids potential anti-metastatic drugs 120,121.

1.9 Rationale and Hypothesis
Metastatic disease accounts for over 90% of cancer mortalities and there is an urgent
need for therapeutic agents. Modulating or inhibiting any of the various steps that
contributes to metastasis will greatly reduce incidences of cancer mortality. We have
previously studied synthetic oleanolic acid derivatives for their abilities to impair cell
migration—a process that is heavily utilized in multiple steps during the metastastatic
cascade. The newer tricyclic compounds or TBEs resemble the synthetic oleanolic acids,
and contain the same active regions responsible for their potency (Figure 1.8B). TBE-31
has been demonstrated to be particularly potent in anti-inflammatory assays compared to
the synthetic triterpenoids, but their effects on cell migration have not yet been studied.
Given the structural similarities between the synthetic oleanolic derivatives and TBE-31,
we hypothesize that TBE-31 will inhibit cell migration by targeting components of the
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Figure 1.8 The effects of the synthetic oleanane triterpenoids and tricyclic
compounds on cell migration
A) A summary of the effects of CDDO-Im on cell migration. Top, CDDO-Im was found
to alter microtubule dynamics by disrupting the microtubule capping protein, Clip-170,
disrupt microtubule dynamics and organization, and cause a loss of polarity proteins to
the leading edge. Bottom, CDDO-Im was found to inhibit Arp2/3-dependent branched
actin polymerization at the leading edge. Note filopodia are unaffected as their formation
is independent of Arp2/3.
B) The effects of TBE-31 on cell migration are currently unknown.
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cytoskeleton. Therefore, we propose to examine the effects of TBE-31 on the
components of the cytoskeleton necessary for cell migration. More specifically, we aim
to:

1) Characterize the effect(s) of TBE-31 on the actin cytoskeleton and cell
migration.
2) Characterize the effect(s) of TBE-31 on the structure and dynamics of the
microtubule network and cell migration.
3) Determine how TBE-31 interacts with actin.

In doing so, we will broaden our understanding of the molecular biology of TBE-31
and their role in cell migration and help advance the development of the tricyclic
compounds and anti-metastatic agents in general.
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Chapter 2

2.1 Chapter Summary
The migratory and invasive potential of the epithelial-derived tumour cells
depends on epithelial-to-mesenchymal transition (EMT) as well as the reorganization of
the cell cytoskeleton. Here we show that the tricyclic compound TBE-31 directly binds to
actin and inhibits linear and branched actin polymerization in vitro. Furthermore, we
observed that TBE-31 inhibits stress fiber formation in fibroblasts as well as in non-small
lung cancer cells during TGFβ-dependent EMT. Interestingly, TBE-31 does not interfere
with TGFβ-dependent signaling or changes in E-cadherin and N-cadherin protein levels
during EMT. Finally, we observed that TBE-31 inhibits fibroblast and non-small cell
lung tumour cell migration with an IC50 of 1.0 and 2.5 µM, respectively. Taken together,
our results suggest that TBE-31 targets linear actin polymerization to alter cell
morphology and inhibit cell migration.
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2.2 Introduction
Cell migration is essential in numerous physiological processes such as
embryogenesis, immune response, cell differentiation and cell renewal. However, it is
also important in the later stages of cancer metastasis, where cell migration and invasion
allow cancer cells to establish secondary tumour sites, which accounts for over 90% of
cancer related deaths 1.
Epithelial cells are normally non-motile, organized in an apical-basal polarity, and
multiple cell-to-cell adhesions help assemble epithelial cells into a sheet-like formation 25

. In order for epithelial based tumours to detach from the primary tumour and migrate,

the cells will have to dissociate these cell-to-cell contacts in a process known as the
epithelial-to-mesenchymal transition (EMT)

2-5

. These biochemical changes, among

others, liberate the epithelial cells and enable them to assume a much more
mesenchymal-like phenotype and prime them for cell migration and invasion 2-5.
Cell migration begins with an initial protrusion of the cell membrane. Newly
forming cell adhesions at the front attach the protrusions to the substratum and provide
traction, while the focal adhesions at the rear disassemble and contractions help retract
the tail. As this occurs repeatedly the cell translocates across the substratum

6-8

. This

process relies on the localization of polarity proteins and the reorganization of different
components of the cytoskeleton, which consists of the microtubule network, intermediate
filaments and the actin cytoskeleton. Although all the cytoskeletal components act in
concert, it is the actin cytoskeleton that provides the force necessary for translocation.
The localization of Rac1 or Cdc42 towards the leading edge with other polarity proteins
is a key regulatory event that stimulates actin polymerization and results in membrane
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protrusion towards the direction of migration. G-actin subunits polymerize to form actin
filaments creating filopodia and lamellipodia. Cdc42 and formins regulate actin
polymerization to form long unbranched bundles of actin to form filopodia, which are
thought to act as sensors that can probe for external cues. Rac1 activates actin related
proteins 2 and 3 (Arp2/3), causing it to bind to preexisting bundles of actin and promote
branched actin polymerization to form lamellipodia, which are broad sheet like
protrusions that drive the cell forwards 6-8. Bundles of actin also form stress fibers to give
a cell its shape and work with focal adhesions and myosin to produce contractile forces in
cell migration 9,10. Since EMT and cell migration are necessary processes for tumour cell
metastasis, chemotherapeutic drugs that target various aspects of these processes are
continuously sought.
Triterpenoids are a family of naturally occurring compounds biologically
synthesized in plants by the cyclization of squalene. They are a chemically diverse family
with over 20,000 known compounds 11,12. Although oleanolic acid is of particular interest
because of its anti-inflammatory and anti-tumourigenic properties, these potencies are
relatively weak

11-14

. Continuous synthetic modifications on oleanolic acid led to 2-

cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid (CDDO), which has much higher antiinflammatory and cytoprotective potency than oleanolic acid, as well as its imidazolide
(CDDO-Im) and its methyl ester (CDDO-Me)

11-16

. They have been demonstrated to

effectively inhibit cytokines from inducing the formation of inducible nitric oxide
synthase in macrophage cells and inducing phase 2 cytoprotective enzymes, both of
which help prevent a cancer causing environment. In addition, they were found to inhibit
proliferation, induce differentiation, and induce apoptosis in cancer cells in vitro. They
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have also been shown to inhibit carcinogen induced primary tumour growth, orthotopic
and ectopic tumour formation, as well as lung metastasis in multiple experimental animal
models 11,12,17-22.
Recently, we have observed that CDDO-Im and CDDO-Me have a number of
effects on the cytoskeleton, leading to the interference of physiological processes that
depend on them

23,24

: CDDO-Im was observed to disrupt the microtubule network,

displacing the polarity proteins IQGAP1 and Rac1 from the leading edge of migrating
cells to abrogate cell polarity 23. Branched actin polymerization depends on the binding of
actin related protein 2/3 (Arp2/3) to preexisting bundles of actin to provide a nucleation
site and allow for branches of actin to polymerize, and CDDO-Im and CDDO-Me were
both found to inhibit the actions of Arp2/3 24. Together these actions potently inhibit cell
migration 23,24.
Structure-activity studies on the parental pentacyclic compounds have revealed
that the 2-cyano-1-en-3-one in ring A and a 9(11)-en-12-one in ring C are responsible for
the potency of these compounds. Therefore new tricyclic compounds, termed tricyclic
bis(enone) compounds (TBEs), were generated and which have great potential for
structural diversity, robust pharmacokinetic and pharmacodynamic profiles

25-27

. In the

pool of semisynthetic triterpenoids and synthetic TBEs, TBE-31 (Figure 2.1B) is one of
the most potent compounds
profound

and

25-27

.

dose–dependent

The oral administration of TBE-31 resulted in a
induction

of

the

cytoprotective

enzymes,

NAD(P)H:quinone oxidoreductase 1 (NQO1) and glutathione S-transferases in the
stomach, skin, and liver of mice, and indicated excellent oral bioavailability

28

. Also,

long-term topical daily applications of TBE-31 caused a robust systemic induction of the
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Figure 2.1 Chemical structures of pentacyclic triterpenoids and the acetylenic
tricyclic bis-(cyano enone), TBE-31.
A) The basic pentacyclic triterpenoid structure. CDDO-Im, which contains an
imidazolide group, is used in this study.
B) The acetylenic tricyclic bis-(cyano enone), TBE-31 and below is shown the
biotinylated TBE-31, TBE-56.
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Keap1/Nrf2/ARE pathway and decreased 6-thioguanine incorporation in DNA of skin,
blood, and liver of azathioprine–treated mice, indicating extraordinary bioavailability and
efficacy

29

. Furthermore, TBE-31 is orally highly protective against aflatoxin–induced

liver cancer in rats 30.
To examine protein targets of TBE-31, a biotin conjugate of TBE-31, TBE-56,
which is obtained from TBE-55, was designed and synthesized

31

. In the present study,

we investigated the effect(s) of TBE-31 on the actin cytoskeleton, and have determined
that unlike the CDDO analogues, TBE-31 binds directly to actin to inhibit
polymerization, and by doing so, TBE-31 also inhibits stress fiber formation during EMT
as well as NSCLC tumour cell migration. Therefore, TBE-31 is an exciting prospect for
multi-targeted inhibition of metastatic potential.
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2.3 Methods
2.3.1 Cell Culture, Antibodies and Reagents
Rat2 and NIH 3T3 fibroblasts were cultured in Dulbecco’s modified Eagle’s
Medium (DMEM). A549 lung adenocarcinomas were cultured in Kaighn's Modification
of Ham's F-12 Medium (F-12K) and H1299 human non-small cell lung carcinoma cells
were cultured in Roswell Park Memorial Institute 1640 medium (RPMI-1640). All cells
were cultured in a 37°C incubator with 5% CO2, and all media was supplemented with
10% fetal bovine serum (FBS) unless otherwise stated.
AlexaFluor 555 conjugated phalloidin (A34055) was purchased from Invitrogen.
Anti-Smad2/3 (BD610843), anti-E-Cadherin (BD610182), anti-N-Cadherin (BD610921)
and anti-Paxillin (BD610051) were purchased from BD transduction Laboratories
(Mississauga, Ontario). Anti-Phospho-Smad 2 (AB3849) was purchased from Millipore.
Cytochalasin D (C8273), Anti-Arp3 (A5979) was purchased from Sigma-Aldrich.
NeutrAvidin Agarose beads (29200) was purchased from Thermo Scientific. Biotin
Azide (PEG4 carboxamide-6-Azidohexanyl Biotin) (B10184) was purchased from Life
Technologies. CDDO-Im and TBE-31 compounds were provided by Dr. Michael B.
Sporn (Dartmouth, NH). The purified actin (AKL99), Arp2/3 (RP01), VCA domain of
WASP (VCG03) and actin polymerization kits (BK003) were purchased from
Cytoskeleton Inc.
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2.3.2 Immunofluorescence microscopy
In all immunofluorescence microscopy studies, cells were fixed in 4%
paraformaldehyde for 10 min, permeabilized in 0.25% Triton X-100 for 5 min, blocked in
10% FBS, and immunostained overnight with the appropriate primary antibodies. All
images were taken with an Olympus IX81 inverted epifluorescence microscope.

2.3.3 Scratch Assays and Immunofluorescence Microscopy
H1299 or NIH 3T3 cells were grown to confluence, and the monolayer was
scratched with a pipette tip. DMSO, and varying concentrations of TBE-31 and CDDOIm were added to their appropriate media, and incubated at standard conditions. For
scratch assays, bright field images were obtained at 0 h with an Olympus IX81
microscope and the same coordinates were reimaged after 18 h (H1299 cells) or 12 h
(NIH 3T3 cells). The extent of cell migration was measured by finding the difference in
width of the scratch between 0 h and final time point. To generate videos, an Olympus
IX81 inverted microscope was fitted with a custom chamber which allowed us to
maintain a temperature of 37°C and an atmosphere containing 5% CO2. Bright field
images were collected at regular 15 min intervals over the duration of the experiment. For
immunofluorescence studies, Rat2 cells were scratched and given 4 h to polarize, before
incubating in media containing DMSO, 1.0 µM of TBE-31, or 1.0 µM of CDDO-Im for 2
h. The cells were then fixed, permeabilized and immunostained with anti-Arp3 antibody,
phalloidin for filamentous actin, and DAPI for the nuclei.
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2.3.4 Subconfluent Cell Migration
Subconfluent NIH3T3 or H1299 cells were grown and treated with DMSO, 1 μM
TBE-31 or 0.5 μM CDDO-Im. Time-lapse observations were made using an Olympus
IX81 inverted microscope equipped with a custom chamber which allowed us to maintain
a temperature of 37°C and an atmosphere containing 5% CO2. Bright field images were
collected at 10 min intervals over 18 h. Distance of migration was determined by tracking
the positions of cell nuclei over 18 h using the MtrackJ plugin 32 for imageJ software 33.

2.3.5 In Vitro Actin Polymerization
In vitro actin polymerization experiments were carried out using a modified
version of the protocol supplied by Cytoskeleton Inc. Purified pyrene labeled actin was
resuspended and incubated in general actin buffer provided by the Cytoskeleton Inc. for 1
h on ice to depolymerize any actin oligomers followed by microcentrifugation at 4 °C for
30 min. Two µM actin (Actin) or actin in the presence of 100 nM VCA domain of nWASp protein and 13 µM Arp2/3 complex (AVA) were incubated with DMSO, or 100
µM of TBE-31 for 15 min on ice, before adding the actin polymerization buffer and
warming the mixtures to 37°C to initiate polymerization. The change in fluorescence was
measured with a Wallac Victor3 V plate reader.
As a control, actin was fully polymerized in the absence of treatment (30 min) and
the fluorescence intensity was measured. DMSO, 100 µM TBE-31 or 100 µM CDDO-Im
was then added and the fluorescence intensity was immediately re-measured to ensure
that these molecules do not interfere or quench the fluorescence intensity.
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2.3.6 Actin Stress Fiber Repolymerization
A subconfluent layer of NIH 3T3, H1299 or Rat2 cells grown on coverslips
incubated in media containing 5 μM of cytochalasin D for 30 min at 37°C. Afterwards,
the cells were rinsed with clean media to remove cytochalasin D, before reincubating in
media containing either DMSO, 1 μM TBE-31, or 1 μM CDDO-Im. At various time
points after reintroducing the new media, the cells were fixed permeabilized, and labeled
for actin using AlexaFluor 555-conjugated phalloidin.

2.3.7 Affinity Pull-downs
Rat2 lysates incubated with DMSO, biotin, TBE-55, or TBE-56 at 4°C for 2 h,
followed by incubating with NeutrAvidin beads for 1 h at 4°C to precipitate the proteins
interacting with the biotin conjugate, TBE-56. Afterwards, the beads were thoroughly
washed, and 2X Laemmli sample prep buffer was added. These samples were then
subjected to SDS-PAGE, and silver staining was performed. Proteins that were uniquely
stained in the TBE-56 samples were excised from the gel, trypsinized and analyzed by
electrospray mass spectrometry. To confirm our results, the same pull-down experiments
from above were performed with cell lysates or purified actin proteins, immunoblotting
with anti-actin was performed after subjecting the samples to SDS-PAGE. For
competitive binding studies, additional samples were added where TBE-31 or TBE-55
were incubated with lysates 1 h before incubating with TBE-56, followed by the same
steps as above.
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2.3.8 Epithelial-to-mesenchymal transition
A549 cells were incubated with 0.2% FBS F-12k media for 4 h, before the
addition of 200 pM TGFβ was added for 48 h at 37°C to initiate an epithelial-tomesenchymal transition. For immunofluorescence studies the cells were grown on
coverslips and fixed, permeabilized and immunostained with monoclonal paxillin
antibody, and AlexaFluor 555 conjugated phalloidin for filamentous actin after the 48 h
treatment. For western blot analysis, the cells were lysed, subjected to SDS-PAGE and
immunoblotted for E-Cadherin, N-Cadherin, Smad2/3, Phospho-Smad2 or actin.
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2.4 Results
A hallmark of epithelial derived tumours is unregulated cell growth, and in many
cases, the later stage of tumour progression is that cells undergo metastasis to migrate
away from the primary tumour site and invade distant organs to establish secondary
tumours

2,34-37

. Therefore the development of chemotherapeutic agents that can inhibit

different aspects of metastasis, including EMT and cell migration, will play a critical role
in reducing in the rate of cancer mortality. EMT and cell migration are dependent on the
reorganization of the cytoskeleton, and the actin cytoskeleton has been proposed to be a
feasible target in tumour metastasis 38.

2.4.1 TBE-31 does not alter Arp3 localization in polarized cells
Cell migration is dependent on the proper localization of proteins involved in
maintaining cell polarity (for e.g., Cdc42/Rac1 and IQGAP1) as well as proteins involved
in the formation of the lamellipodia via Arp2/3-dependent branched actin polymerization
at the leading edge of migrating cells

6-8,39-41

. We previously demonstrated that CDDO-

Im displaces Arp2/3 from the leading edge, reduces branched actin polymerization and
inhibits cell migration

23,24

. TBE-31 contains a similar structural core as the pentacyclic

triterpenoids (Figure 2.1) and has been shown to induce the Keap1/Nrf2/ARE pathway in
a similar fashion as the pentacyclic compounds
on the cytoskeleton remain unknown.

28,29

. However, the effect(s) of TBE-31

We therefore used immunofluorescence

microscopy to examine if TBE-31 would target the cytoskeleton by first assessing if it
targets the Arp2/3 complex and displaces it from the leading edge of migrating cells as
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efficiently as CDDO-Im. Briefly, Rat2 fibroblasts were grown to confluence, scratched
and allowed to polarize before being treated with DMSO, 1 μM TBE-31 or 1 μM CDDOIm. The cells were then immunostained for Arp3 and filamentous actin, followed by
processing for immunofluorescence microscopy (Figure 2.2A). We observed that 88 ±
3% of the cells treated with DMSO exhibited Arp3 localization at the leading edge, while
CDDO-Im reduced leading edge staining of Arp3 to 53 ± 18% (Figure 2.2), consistent
with our previous observations

24

. Interestingly, TBE-31 did not alter leading edge

staining of Arp3 compared to the cells treated with vehicle (Figure 2.2). This was
intriguing because the core of the CDDO-Im molecule (similar to the TBE-31 core) was
modeled to fit into the Arp3 inhibitory groove 24, similar to the bona fide Arp3 inhibitor,
CK-869 42. The lack of displacement of Arp3 from the leading edge in cells treated with
TBE-31 suggests that the compound is not associating and interfering with the subcellular
localization of Arp3. Therefore, in order to assess the binding of TBE-31 with Arp3
and/or or other cytoskeletal proteins, we next carried out a pull-down approach.

2.4.2 TBE-31 binds to actin directly
To determine the binding partners for TBE-31, cell lysates were incubated with
either DMSO or TBE-56, followed by precipitation with NeutrAvidin beads. Proteins
associating with TBE-56 were separated on SDS-PAGE, processed and analyzed by mass
spectrometry (Figure 2.3A). Although we previously used this approach to identify that
CDDO-Me associated with Arp3

24

, we were unable to detect an association between

TBE-56 and Arp3. The main cytoskeletal protein that was identified to associate with
TBE-56 was actin and we further analyzed this interaction by immunoblot analysis
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Figure 2.2 TBE-31 does not alter Arp3 localization to the cell periphery
A) Confluent monolayers of Rat2 fibroblasts were scratched and incubated at 37°C in
DMEM supplemented with 10% FBS for 4 hours to allow them to polarize. Cells were
then incubated for 2 h in media containing DMSO, 1 µM CDDO-Im, or 1 µM TBE-31.
The cells were then fixed, permeabilized and immunostained with Arp3 (green),
AlexaFluor 555 phalloidin (red) for filamentous actin and DAPI (blue) for the nuclei.
Shown here are representative immunofluorescence images taken with an Olympus IX81
microscope at 40x magnification. Bar = 10 µm. The arrows highlight staining of Arp3 at
the cell periphery.
B) Experiments were carried out as described in panel A, quantitated and graphed for the
number of cells containing leading edge staining for Arp3 (n=3±SD, *p<0.05).
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Figure 2.3 TBE-31 binds to actin
A) Rat2 fibroblasts were incubated with either 10 µM biotin, TBE-55 or biotinylatedTBE-31 (TBE-56), lysed, and incubated with NeutrAvidin-agarose beads. SDS-PAGE
and silver staining were performed and proteins that were uniquely stained in TBE-56treated samples were excised from the gel, trypsinized, and analyzed by electrospray
mass spectrometry. Protein identifications are indicated on the right of the gel. Nonspecific binding labeled as NS. (n=3)
B) Rat2 lysates or purified actin were incubated with either DMSO, TBE-55, or
biotinylated-TBE-31 (TBE-56) at 4°C for 2h, followed by incubating with NeutrAvidin
beads for 1h at 4°C to precipitate the proteins interacting with TBE-56. Afterwards, the
beads were thoroughly washed, and sample prep buffer was added. These samples were
then subjected to SDS-PAGE, followed by immunoblotting for actin. Shown here is a
representative immunoblot (n=3).
C) To perform competitive binding studies similar experiments were performed as
described in Panel B. Additional samples were add that had been pretreated with
increasing concentrations of TBE-31 or TBE-55, before incubating with biotinylated
TBE-31 (TBE-56). Shown here is a representative immunoblot (n=3)
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(Figure 2.3B). Briefly, Rat2 lysates were incubated with DMSO, TBE-55 or TBE-56,
precipitated with NeutrAvidin beads and processed for immunoblotting with actin
antibodies and we observed that TBE-56 associated with actin in cell lysates (Figure
2.3B, left panel). In order to assess if this interaction was direct, we carried out the pulldown assay using purified actin and observed similar results (Figure 2.3B, right panel),
suggesting that TBE-56 does indeed bind directly to actin and not through an associated
binding partner. Furthermore, we performed competitive binding assays where Rat2
lysates were pretreated with either DMSO, or increasing concentrations of TBE-31 or
TBE-55, before incubating with TBE-56. We found that by increasing the concentrations
of TBE-31 or TBE-55 in the pretreatment, actin was unable to be precipitated by the
biotin conjugate, TBE-56 (Figure 2.3C).
These results suggested that biotinylated TBE-31 is able to associate with actin
but not Arp3. We next assessed if the tricyclic compound would have an effect on linear
vs. actin polymerization in vitro.

2.4.3 TBE-31 inhibits actin polymerization
Actin is a globular multifunctional protein that binds end-to-end to form
filaments, which can provide a basis for contractile forces, cell protrusions or structure
6,7,9,10,43

. We examined the effects of TBE-31 on actin dynamics by assessing in vitro

polymerization of actin (Figure 2.4A). Briefly, purified pyrene labeled actin was
incubated on ice to depolymerize any actin oligomers. Actin was incubated in the
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Figure 2.4 TBE-31 inhibits actin polymerization and stress fiber formation
A) Purified pyrene-labeled actin was polymerized in the presence of DMSO (vehicle), 5
μM cytochalasin D (Cyto. D; top panel), 100 μM CDDO-Im (middle panel) or 100 μM
TBE-31 (bottom panel). For branched actin polymerization 100 nM VCA domain of nWASp protein and 13 μM Arp2/3 complex in addition to the Actin (AVA). Actin
polymerization was measured by pyrene fluorescence and graphed as fluorescence
intensity (arbitrary units) versus time (min). (n=3 ± SEM). Note: All the conditions in
the graphs were carried out together and the results are separated into three graphs for the
sake of clarity. The control conditions (gray lines) are shown in each graph to indicate
the differences in vehicle vs. compound treated samples.
B) To ascertain that the addition of TBE-31 or CDDO-Im would not quench pyrene-actin
fluorescence intensity, pyrene actin polymerization was carried out as described in the
Materials section, measured (-) and then DMSO, TBE-31 or CDDO-Im were added to the
samples and re-measured (+) for fluorescence intensity.

Note that the fluorescence

intensity did not appreciably change after vehicle or drug addition.
C) A subconfluent layer of NIH 3T3 cells were grown on coverslips and incubated in
DMEM supplemented with 5 μM cytochalasin D at 37°C for 30 min to depolymerize the
actin cytoskeleton. Afterwards, the cells were rinsed with PBS to remove the previous
treatments. Media supplemented with DMSO, 1 μM TBE-31, or 1 μM CDDO-Im was
then reintroduced to the cells while the actin stress fibers repolymerized in the absence of
cytochalasin D. The cells were then fixed, permeabilized and immunostained with
AlexaFluor 555 phalloidin to visualize actin filaments (red), and DAPI (blue) for the
nuclei. Shown here are representative immunofluorescence images taken with an
Olympus IX81 microscope at 40x magnification (n=3). Bar=20 μm.
D) Quantitation of cells with actin stress fibers (inset; white arrows) was carried and
graphed (bottom panel; n=3± SEM, *p<0.05). Quantified cells were differentiated from
cells containing cortical actin staining (inset; yellow arrowhead).
E) A subconfluent layer of Rat2 fibroblasts were grown on coverslips and incubated in
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media supplemented with 5 μM cytochalasin D at 37°C for 30 min to depolymerize the
actin cytoskeleton. Afterwards, the cells were rinsed with PBS to remove the previous
treatments. Media supplemented with DMSO, 1 μM TBE-31, or 1 μM CDDO-Im was
then reintroduced to the cells while the actin stress fibers re-polymerized in the absence
of cytochalasin D. The cells were then fixed, permeabilized and immunostained with
AlexaFluor 555 phalloidin to visualize actin filaments (red), and DAPI (blue) for the
nuclei. Shown here are representative immunofluorescence images taken with an
Olympus IX81 microscope at 40x magnification (n=3). Bar=20 μm.

Inset:

Representative areas were magnified to demonstrate actin stress fibers (white arrows) or
areas of branched actin polymerization (blue arrowheads). Note that TBE-31 treatment
reduced the length of stress fibers but did not inhibit branched actin polymerization.
However, CDDO-Im treated Rat2 fibroblasts contained actin stress fibers comparable to
vehicle-treated cells but contained reduced branched actin polymerization.
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presence of DMSO (vehicle), TBE-31, CDDO-Im or cytochalasin D (CD) for 15 min on
ice, before adding the actin polymerization buffer and warming the mixtures to 37°C to
initiate polymerization. To induce branched actin polymerization, Arp2/3, and the VCA
domain of n-WASp was added in addition to the Actin (AVA). By recording the change
in fluorescence intensity, we measured the rate of polymerization. cytochalasin D is a
well-established mycotoxin that reversibly binds with globular actin monomers to prevent
polymerization 44,45. As expected, cytochalasin D inhibited the rate of linear and branched
actin polymerization (Figure 2.4A, top panel). CDDO-Im inhibited the Arp2/3 mediated
branched actin polymerization and had little effect on the polymerization rate of linear
actin (Figure 2.4A, middle panel). This was expected, as we have previously
demonstrated that CDDO-Im only acts on Arp2/3 to inhibit Arp2/3 mediated branched
actin polymerization

24

. Interestingly, TBE-31 was able to inhibit both branched and

linear actin polymerization (Figure 2.4A, bottom panel). Furthermore, TBE-31 also
reduced the total overall amount of polymerized actin by approximately 40%, suggesting
that unlike cytochalsin D, which is capable of depolymerizing filamentous actin, TBE-31
may be sequestering monomeric actin and preventing it from being incorporated into
growing filamentous actin fibers. Finally, to ascertain that the addition of the tri- or
penta-cyclic compounds was not interfering with the fluorescence of the pyrene actin in
the assay, we allowed actin to fully polymerize and then incubated the polymerized actin
in the presence or absence of DMSO (control) CDDO-Im or TBE-31 (Figure 2.4B). We
observed that the addition of the tri or penta-cyclic compounds did not quench the
fluorescent signal.
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Taken together, these results are intriguing because CDDO-Im and CDDO-Me
were found to inhibit cell migration by blocking branched actin polymerization

24

,

however TBE-31 may affect cell migration by targeting general actin polymerization.
We therefore next assessed the effect TBE-31 would have an effect to actin
polymerization in cells.
Actin polymerization in cell culture was also examined in parallel with our in
vitro experiments by examining actin stress fiber formations in NIH 3T3 fibroblasts.
Briefly, NIH 3T3 fibroblasts were incubated for 30 min in media containing cytochalasin
D to completely depolymerize the actin stress fibers. Afterwards, cytochalasin D was
removed and the cells were incubated in media containing DMSO, TBE-31, or CDDO-Im
while the actin cytoskeleton re-polymerized. At various time points, the cells were fixed,
permeabilized, and labeled for filamentous actin using phalloidin. Immediately after
cytochalasin D treatment, actin filaments were completely depolymerized, causing the
cells to round up and lose their polarized morphology (Figure 2.4C, top panel). However,
after removing the cytochalasin D and incubating cells in the presence of DMSO or
CDDO-Im, the actin re-polymerized and formed stress fibers. Interestingly, TBE-31treated cells did not reestablish elongated stress fibers (Figure 2.4C, top panel). Closer
examination showed that only short, cortical stress fiber formation was occurring (Figure
2.4C, inset). Quantitation of these cells for cells with actin stress fibers vs. cells without
stress fibers supported our observations. By two hours DMSO, CDDO-Im, and TBE-31
treated cells had 47 ± 1%, 40 ± 3% and 39 ± 5% of cells with stress fibers formed
respectively (Figure 2.4D). By six hours DMSO and CDDO-Im treated cells had 69 ± 3
% and 73 ± 2% recovery of stress fibers, while TBE-31 treated cells had lagged behind
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with only 43 ± 4%. Similar results were obtained using Rat2 fibroblasts (Figure 2.4E).
These results further support the idea that TBE-31 inhibits actin polymerization and
predict that stress fiber formation would be inhibited in tumour cells undergoing
epithelial to mesenchymal transition.

2.4.4 TBE-31 inhibits TGFβ-dependent actin stress fiber formation
during epithelial-to-mesenchymal transitions
During epithelial-to-mesenchymal transitions, the actin cytoskeleton rearranges
from a cortical alignment associated with cell-cell junctions into actin stress fibers, which
are associated with cell migration

3,5

. We therefore investigated whether TBE-31 would

have an effect on the actin-dependent changes that occur during EMT. Briefly, non-small
cell lung cancer (NSCLC) A549 cells were incubated in serum-free medium or medium
containing TGFβ for 48 h, and either DMSO or TBE-31. Afterwards, the cells were
fixed, permeabilized and immunostained with paxillin antibody and phalloidin to
visualize filamentous actin. Under bright field microscopy we observed a cobble stone
phenotype associated with epithelial cells in the cells that were not stimulated with TGFβ,
regardless of the addition of DMSO or TBE-31 (data not shown). These cells only
demonstrated cortical actin staining with little to no stress fibers, which is another
characteristic of epithelial cells (Figure 2.5A). Conversely, the cells stimulated with
TGFβ in the presence of DMSO demonstrated an elongated, and spindle like phenotype
and under immunofluorescence microscopy these cells also demonstrated proper stress
fiber formation (Figure 2.5A), all of which are associated with a more mesenchymal
phenotype. TGFβ stimulation in the presence of TBE-31 resulted in less stress fiber
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Figure 2.5 TBE-31 inhibits TGFβ-dependent actin stress fiber formation during
NSCLC tumour cell EMT
A) Serum starved A549 cells, were incubated in the presence or absence of TGF and
with DMSO or 1 µM TBE-31 for 48 h at 37°C. The cells were then fixed permeabilized
and immunostained with monoclonal paxillin antibody (green), and AlexaFluor 555
conjugated phalloidin (red) for filamentous actin. Shown here are representative
immunofluorescence images at 40x magnification (n=3). Bar = 10 µm. Insets highlight
area of interest and indicate actin stress fibers (white arrows) vs. cortical actin staining
(yellow arrowhead).
B) Serum starved A549 cells, were incubated in media supplemented with 200 pM TGFβ
and either DMSO or 1 µM TBE-31 for 30 min at 37°C. Cells were lysed prior to TGFβ
stimulation, and 0.5 h, 1.5 h and 4.5 h after stimulation. Lysates were subjected to SDSPAGE and immunoblotted for p-Smad2, and Smad2 (n=4).
C) A549 cells were serum starved for 4 h, before incubating in media containing 200 pM
TGFβ and either DMSO, 1 µM TBE-31, or varying concentrations of cytochalasin D for
48 h. Cells were subsequently lysed, subjected to SDS-PAGE and immunoblotted for ECadherin, N-Cadherin, or Actin (n=3).
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formation and elongation; instead they displayed the cobblestone phenotype associated
with epithelial cells (Figure 2.5A). These results suggest that TBE-31 inhibits the actin
related changes in EMT induced by TGFβ.
In order to assess if the inhibition of actin stress fiber formation in the A549 cells
was due to an inhibition of the EMT process, we examined TGFβ signal transduction by
examining Smad2 phosphorylation to ensure TBE-31 was not interfering with TGFβ
signaling. Briefly, A549 cells were serum starved for 4 h before treatment with DMSO,
TBE-31 or varying concentrations of cytochalasin D for 30 min. Afterwards, TGFβ was
added to the media and was allowed to incubate for another 30 min before being lysed,
subjected to SDS-PAGE, and immunoblotted for P-Smad2, Smad2 and actin. We
observed that regardless of the pharmacological treatment, TGFβ was able to induce the
phosphorylation of Smad2, suggesting that none of our treatments affected the TGFβ
signaling pathways (Figure 2.5B).
To further verify proper TGFβ signaling, we examined other biochemical changes
that mark EMT. E-cadherin is the major component of epithelial adherens junctions,
which form a belt-like structure around the cells to tether adjacent cells into an immobile
sheet-like formation. During EMT the expression of E-cadherin becomes down regulated,
which liberates the cells from one another. Conversely the expression of N-Cadherin, an
adhesion molecule associated with highly migratory mesenchymal cells, becomes up
regulated. This is known as the cadherin switch and is a major hallmark of EMT

2-5

.

These changes were examined by treating A549 cells with TGFβ for 48 h in the presence
or absence of DMSO, TBE-31 or cytochalasin D, subjected to SDS-PAGE and
immunoblotted for E-Cadherin and N-Cadherin (Figure 2.5C). Regardless of treatment,

88

TGFβ stimulation led to a decrease in E-cadherin expression, while N-cadherin
expression increased. This suggested that a proper cadherin switch was occurring in the
presence of TGFβ in vehicle, TBE-31 or cytochalasin D-treated cells and further
reconfirms that TBE-31 does not have an effect on TGFβ signaling, or gene transcription
associated with EMT.

2.4.5 TBE-31 inhibits cell migration
We next focused our attention on cell migration, another actin-dependent process
that follows EMT in metastasis. Actin polymerization provides the main driving force in
cell migration, and we have previously shown that the triterpenoids CDDO-Im and
CDDO-Me inhibit the Arp2/3 mediated branched actin polymerization by binding to
Arp2/3 and decrease the rate of cell migration 24. Since we have demonstrated that TBE31 is able to bind to actin directly and modify its polymerization into stress fibers, we
next assessed if it could inhibit cell migration as well. To assess this, we used H1299
human non-small cell lung carcinoma cells as well as migrating fibroblasts (NIH 3T3
cells), which exhibited robust migration in our scratch assays (Figure 2.6). In brief,
H1299 or NIH 3T3 cells were grown to confluence and scratched to stimulate migration.
The cells were then incubated in either DMSO, or varying concentrations of TBE-31 or
CDDO-Im. We observed that after 18 h, DMSO treated H1299 cells had migrated on
average 432 ± 25 µm, whereas the NIH 3T3 cells had migrated 545 ± 30 µm after 12 h.
Overall, TBE-31 or CDDO-Im treated cells demonstrated a dose-dependent decrease in
cell migration (Figure 2.6A, graphs) (Video 2-1). More specifically, the IC50 of TBE-31
for H1299 cells was found to be 2.5 µM and 1 µM for the NIH 3T3 cells.
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Figure 2.6 TBE-31 inhibits NSCLC tumour cell migration
A) Top panel; Confluent monolayers of H1299 lung tumour cells were scratched and
incubated at 37°C in media containing either DMSO, 2 μM TBE-31 or 1 μM CDDO-Im
for 18 h. Shown are representative bright field microscopy images taken with an
Olympus IX81 microscope at 10x magnification at 0 and 18h post-incubation. Bottom
panel; Scratch assays were carried out as described above using varying concentrations of
TBE-31 or CDDO-Im and the relative cell migration was quantitated using ImagePro
software (n=4±SD). *P<0.05.
B) Top panel; Confluent monolayers of NIH 3T3 fibroblasts were scratched and
incubated as described in panel A. Shown are representative bright field microscopy
images taken with an Olympus IX81 microscope at 10x magnification at 0 and 12h postincubation (n=3). Bottom panel; Scratch assays were carried out as described above using
varying concentrations of TBE-31 or CDDO-Im and the relative cell migration was
quantitated using ImagePro software (n=3±SD). *P<0.05.
C) Subconfluent H1299 or NIH 3T3 cells were incubated with vehicle (DMSO), 1 µM
TBE-31 or 0.5 µM TCDDO-Im and imaged over 18 hours. Using Image J software, the
tracking patterns of migrating single cells (multi-color plots) were measured and graphed.
The average distance migrated by the H1299 or NIH 3T3 cells are shown on the right
(n=3 ± SD). *P<0.05.
Video 2.1. TBE-31 inhibits NSCLC tumour cell migration
Confluent monolayers of H1299 lung tumour cells were scratched and incubated at 37°C
in media containing either DMSO (top), 1 μM TBE-31 (middle) or 1 μM CDDO-Im
(bottom) for 18 h. Representative bright field microscopy images were taken at 10x
magnification every 15 min using an Olympus IX81 microscope to create a movie.
Video 2.2. TBE-31 inhibits NIH 3T3 cell migration
Single cell tracking of NIH 3T3 cells was carried out using time-lapse microscopy with
an Olympus IX81 inverted microscope equipped with a custom chamber which allowed
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us to maintain a temperature of 37°C and an atmosphere containing 5% CO2. Bright field
images were collected at 10 min intervals over 18 h. Distance of migration was
determined by tracking the positions of cell nuceli over 18 h using the MtrackJ plugin
(32) for imageJ software (33).

91

92

The IC50 for CDDO-Im was found to be approximately 1 µM, for both cell lines, similar
to our previous results using Rat2 fibroblasts 24.
To confirm that TBE-31 and CDDO-Im were indeed inhibiting the migration of
both tumour and fibroblast cell lines, we carried out single cell tracking studies of H1299
or NIH 3T3 cells (Figure 2.6B).

Briefly, subconfluent populations of cells were

incubated with media containing vehicle (DMSO), CDDO-Im or TBE-31 and imaged for
18 hours. The migration tracks as well as the average distance travelled were calculated
and graphed (Figure 2.6B). (Video 2-2). Consistent with the scratch assays, we observed
that both TBE-31 and CDDO-inhibited NIH 3T3 and H1299 cell migration at low
micromolar concentrations.
Overall, our results show that TBE-31 associates and inhibits actin
polymerization, resulting in reduced tumour cell stress fiber formation and cell migration.
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2.5 Discussion
Although the overall effect of TBE-31 on cell migration are not dissimilar from
CDDO-Im and CDDO-Me (the compounds it was derived from) the effects on actin
polymerization are strikingly different: CDDO-Im and CDDO-Me were shown to only
inhibit Arp2/3 dependent branched actin polymerization and did not have an appreciable
effect on linear actin polymerization

24

. This CDDO-Im-dependent or CDDO-Me-

dependent inhibition of Arp2/3 activity or perhaps branched actin formation was also
associated with an absence of polarity proteins at the leading edge of migrating cell. The
differences in TBE-31 and CDDO compound in their abilities to target linear vs.
branched actin polymerization may also effect polarity protein localization and activity
and will be investigated in future studies. In addition, CDDO-Im demonstrated the ability
to alter microtubule dynamics and organization

23

. Future studies will also examine the

effects of TBE-31 on the microtubule network and the possible impact it may have on
microtubule-dependent processes such protein trafficking, cell signaling, cell division,
mitosis, and cell migration.
The enormous biological diversity of cancer has led to limited promise for therapies
that target single signaling molecules. It has been suggested that strategic combinations
of agents targeting against the most critical alterations in cancer will be needed, or simply
the use of more unspecific agents that modulate several relevant targets simultaneously
46,47

. Not surprisingly, drug discovery has moved towards investigating multi-target drugs

in the last decade, in a large part due to the development of cancer therapeutics

48-50

.

TBE-31 is an attractive compound for cancer prevention due to its antioxidative, antiinflammatory response capabilities by inducing the Keap1/Nrf2/ARE pathway

25-29

, and
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now inhibiting cell migration by targeting actin. The parallels and contrasts between
TBE-31 and the CDDO analogs may lend well to combinational therapies with cytotoxic
drugs. The possibility for these and other synergistic effects between TBE-31 and drugs
already used in the clinic will provide us with future avenues of research.
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Chapter 3

3.1 Chapter Summary
Cell migration is dependent on the microtubule network for structural support as
well as for the proper delivery and positioning of polarity proteins at the leading edge of
migrating cells. Identification of drugs that target cytoskeletal-dependent cell migration
and protein transport in polarized migrating cells is important for understanding the cell
biology of normal and tumour cells and can lead to new therapeutic targets in disease
processes. Here, we show that the tricyclic compound TBE-31 directly binds to tubulin
and interferes with microtubule dynamics, as assessed by end binding 1 (EB1) live cell
imaging. Interestingly, this interference is independent of in vitro tubulin polymerization.
Using immunofluorescence microscopy, we also observed that TBE-31 interferes with
the polarity of migratory cells: The polarity proteins Rac1, IQGAP and Tiam1 normally
localized at the leading edge of DMSO-treated migrating cell, but were observed to be in
multiple protrusions around the cell periphery of TBE-31-treated cells. Finally, we
observed that TBE-31 inhibits the migration of Rat2 fibroblasts with an IC50 of 0.75 µM.
Taken together, our results suggest that the inhibition of cell migration by TBE-31 may
result from the improper maintenance of cell polarity of migrating cells.
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3.2 Introduction
Epithelial cells are normally organized with apical-basal polarity, and multiple
cell-to-cell junctions and adhesions maintain the barrier function in non-motile sheet-like
formations. During epithelial-to-mesenchymal transition (EMT), epithelial cells undergo
changes in the signaling pattern that define cell shape

1-4

. The cell-to-cell junctions and

apical basal polarity are lost, the cytoskeleton reorganizes, and the overall motility of the
cells is enhanced 1-4. EMT is an essential process during organ development as well as in
wound healing. However, during cancer progression, EMT acts as a precursor event to
metastasis, unmasking the migratory and invasive potential of the tumour cells. Like
EMT, cell migration is necessary in normal physiological conditions, such as
embryogenesis, immune response, and wound healing, but during cancer metastasis cell
migration and invasion allow cancer cells to establish secondary tumour sites, which
accounts for over 90% of cancer related deaths 5-10.
Cell migration begins with an initial protrusion of the cell membrane at the
leading edge of the cell. Nascent adhesions attach the protrusion to the substratum, while
mature focal adhesions at the rear disassemble. This occurs repeatedly to translocate the
cell across the substratum. These events rely on the dynamic nature and coordination
between the actin cytoskeleton and the microtubule network

7-10

. Tubulin heterodimers,

formed by α and β subunits, polymerize to form microtubules, slender filamentous tubes
that emanate from the microtubule-organizing center (MTOC). The microtubule network
is highly dynamic, constantly polymerizing and depolymerizing, and is tightly regulated,
both spatially and temporally

11

. During cell migration the microtubule network

reorganizes to establish a structural skeleton for front-rear polarity. Polarity proteins such
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as Rac1 and Cdc42 are asymmetrically trafficked to the leading edge via Rab5 positive
endosomal vesicles along microtubules

11-13

. This stimulates the rearrangement of the

actin cytoskeleton, and initiates polymerization to provide the membrane necessary for
protrusion

7-10

. Since cell migration is necessary for tumour cell metastasis and cancer

progression, chemotherapeutic agents that target aspects of this process are continually
sought.
The semi-synthetic oleanane triterpenoids are a class of multifunctional
compounds that were observed to inhibit cell migration by targeting microtubule
dynamics as well as actin related protein 2/3 (Arp2/3)-dependent branched actin
polymerization

14,15

. Analysis of these pentacyclic compounds identified that the 2-

cyano-1-en-3-one in ring A and a 9(11)-en-12-one in ring C are responsible for drug
action (Figure 3.1A). Therefore new tricyclic compounds, termed tricyclic bis(enone)
(TBE) compounds were generated. TBEs have great potential for structural diversity as
well as more robust pharmacokinetic and pharmacodynamic profiles

16-18

. Of these

compounds, TBE-31 (Figure 3.1A) was shown to be most potent in in vitro antiinflammatory assays

16-18

and we previously determined that TBE-31 binds directly to

actin to inhibit linear actin polymerization

19

. TBE-31 inhibits stress fiber formation

during EMT as well as non-small cell lung cancer tumour cell migration 19. Interestingly,
the mechanism(s) that TBE-31 utilizes to inhibit cell migration are distinct from the
pentacyclic triterpenoids, despite having common predicted reactive rings

14,15,19

.

Therefore, the identification and understanding of which proteins associate and are
modulated by TBE-31 will be of great benefit for developing anti-cancer agents. In the
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present study, we investigated the effect(s) of TBE-31 on the dynamics of the
microtubule network and the positioning of polarity proteins in migrating cells.
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3.3 Materials and Methods
3.3.1 Cell Culture, Antibodies and Reagents
Rat2 fibroblasts were cultured in Dulbecco’s modified Eagle’s Medium (DMEM).
Mv1Lu mink lung cells were cultured in minimal essential medium (MEM)
supplemented with 1% non-essential amino acids (NEAA). Mv1Lu cells stably
transfected with HA epitope-tagged TGFβ type II receptor (HAT cells) were cultured in
MEM containing 1% non-essential amino acids and 0.3 mg/mL Hygromycin B
(Invitrogen # 10687-010). All cells were cultured in a 37°C incubator with 5% CO2, and
all media was supplemented with 10% fetal bovine serum (FBS) unless otherwise stated.
Monoclonal anti-Rac1 (cat. # 610650) and anti-EEA1 (cat. # 610457) antibodies
were purchased from BD Biosciences (Mississauga, Ontario). Polyclonal anti-IQGAP1
(H-109; cat. # sc-10792), anti-HA (Y-11; cat. # sc-805), polyclonal anti-Tiam1 (cat. # sc872), and polyclonal anti-Rab 5 (FL-215; cat. # sc-28570) were purchased from Santa
Cruz Technology (Santa Cruz, CA.). Monoclonal anti-tubulin (2.1, cat. # T-4026) was
purchased from Sigma-Aldrich. Monoclonal anti-active Rac1-GTP (cat. # 26903) was
purchased from New East Biosciences. Nocodazole and Paclitaxel were purchased from
Sigma-Aldrich. NeutrAvidin Agarose beads were purchased from Thermo Scientific.
Biotin Azide (PEG4 carboxamide-6-Azidohexanyl Biotin) (cat. # B10184) was purchased
from Life Technologies. The tubulin polymerization kit (cat. # BK006P) and purified
tubulin (cat. # T240) were purchased from Cytoskeleton Inc. TBE-31, CDDO-Im were
used as previously described (16). The biotinylated derivative of TBE-31 (TBE-56) and
the non-biotinylated control (TBE-55) were synthesized as previously described (Figure
3.1A) 20.
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3.3.2 Affinity Pull-downs and Mass Spectrometry
Rat2 lysates were prepared by incubating cells with TNTE lysis buffer (150 mM
NaCl, 0.5 % Triton X-100, 25 mM Tris-Cl [pH 7.4], 5 mM EDTA) for 30 min at 4 ˚C and
centrifuged (15,000 gav) for 10 min to remove cellular debris. The lysates were then
incubated with 0.1% DMSO (vehicle control), 10 µM biotin, 10 µM TBE-55, or 10 µM
TBE-56 at 4°C for 2 h, followed by incubating with NeutrAvidin beads for 1 h at 4°C to
precipitate the proteins interacting with the biotin conjugate, TBE-56. Afterwards, the
beads were thoroughly washed, and 2X Laemmli sample prep buffer was added. These
samples were then subjected to SDS-PAGE, and silver staining was performed. Proteins
that were uniquely stained in the TBE-56 samples were excised from the gel, trypsinized
and analyzed by electrospray mass spectrometry using a Waters, Q-ToF Global mass
spectrometer equipped with a Z-spray source and run in positive ion mode. The peptides
were identified using MASCOT software. To confirm our results, pull-down experiments
were carried out as described above, using cell lysates or 1 µg purified tubulin, followed
by immunoblotting with anti-tubulin (1:1000) antibodies. For competitive binding
studies, additional samples were pre-incubated with TBE-31 or TBE-55 for 1 h before
pull-down studies were performed.

3.3.3 Subcellular Fractionation
Fractions containing the cytoskeleton were separated from those containing
detergent-solubilized membranes and cytosol by the method described by Contin et al 21.
Briefly, Mv1Lu cells were incubated for 2 h in control medium or media containing 10
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μM nocodazole, 1 μM TBE-31 or 1 µM CDDO-Im and then rinsed with microtubule
stabilization buffer (90 mM Mes (pH 6.7), 1 mM EGTA, 1 mM MgCl2, 10% (v/v)
glycerol) that had been preheated to 37 °C. Cells were then lysed with microtubule
stabilization buffer containing 10 μM paclitaxel, 0.5% Triton X-100, and protease
inhibitors for 4 min at 37 °C. The solubilized fractions were then collected. To collect the
remaining cellular structures containing the cytoskeleton, SDS-PAGE sample buffer was
added to the culture dishes. Following scraping and passaging through a syringe, the
fractions containing the cytoskeleton were collected. To analyze the partitioning of
cytoskeletal proteins, fractions containing the soluble proteins or the cytoskeleton were
subjected to SDS-PAGE and immunblotted with monoclonal anti-tubulin (1:1000)
antibody.

3.3.4 Immunofluorescence Microscopy
In all immunofluorescence studies, cells were fixed in 4% paraformaldehyde for
10 min, permeabilized in 0.25% Triton X-100 for 5 min, blocked in 10% FBS, and
immunostained overnight with anti-Rac1 (1:100), anti-Tiam1 (1:100), anti-EEA1 (1:100)
or anti-IQGAP (1:100) antibodies. Following incubation with Alexafluor-488 or -555
labeled secondary antibodies (1:250 dilution) and DAPI staining, cells were imaged using
an Olympus IX81 inverted epifluorescence microscope.
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3.3.5 Leading Edge Immunofluorescence Microscopy
For immunofluorescence studies examining proteins at the leading edge, Rat2
fibroblasts were grown to confluence on glass coverslips, and scratched with a pipette tip.
They were then allowed to elongate and polarize for 4 h, before incubating in media
containing DMSO, 1.0 μM of TBE-31, or 1.0 μM of CDDO-Im for 2 h. The cells were
then fixed, permeabilized and immunostained with the primary and secondary antibodies
as described above. For experiments where cells were probed using TBE-56 (or the TBE55 control), the cells were left untreated before being fixed, permeabilized and
immunostained with the appropriate primary antibodies.

3.3.6 Scratch Assays
Rat2 fibroblasts were grown to confluence, and the monolayer was scratched with
a pipette tip. The cells were then incubated with DMSO (control) or varying
concentrations of TBE-31 or CDDO-Im. An Olympus IX81 inverted microscope was
fitted with a custom chamber maintaining a temperature of 37°C and an atmosphere
containing 5% CO2. Bright-field images were collected over 16 h. The extent of cell
migration was measured by finding the difference in width of the scratch at 0 time and 16
h in triplicate. For washout and recovery experiments, the media was replaced with drug
free media, and the cells were imaged for a further 24 h.
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3.3.7 EB1 Movies
Mv1Lu cells were transfected with GFP-tagged EB1 using PolyJet transfection
reagent (100688) from FroggaBio as per the manufacturer’s protocol. The cells were
then incubated for 48 h before incubating them with media containing DMSO (control) or
1 µM TBE-31. The fluorescent EB1 “comets” were imaged in live cells using an
Olympus IX81 microscope as described above and quantitated using the Fiji tracking tool
for ImageJ 22. EB1 comets (≥ 1000 comets/cell) were imaged and the distances travelled
were quantitated from 10 cells/condition/experiment and graphed (N=3 ± SEM).

3.3.8 TGFβ Receptor Endocytosis
Receptor internalization studies were carried out as previously described

14,23

.

Briefly, HAT cells expressing HA-tagged TGFβ type II receptor (TβRII) were incubated
with anti-HA antibody for 2 h at 4 °C, followed by Alexafluor-555 (1:500) secondary
antibody. Cells were then washed and further incubated at 37 °C for 1 h with DMSO, 1
μM TBE-31, or 1 μM CDDO-Im. Afterwards, the cells were fixed, permeabilized and
immunostained with anti-EEA1, secondary antibodies and DAPI.

3.3.9 In Vitro Tubulin Polymerization
In Vitro tubulin polymerization experiments were carried according to the
standard protocols supplied by Cytoskeleton Inc. In brief, 2 mg/ml of purified tubulin
was polymerized in the presence of either 10 µM TBE-31, 10 µM CDDO-Im, 3 µM
taxol, or 3 µM nocodazole, diluted in the tubulin polymerization buffer provided by
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Cytoskeleton Inc at 37°C 1h. The buffer contained a fluorescent reporter, which allowed
us to measure the rate of polymerization by measuring the change in fluorescence with a
Wallac Victor3 V plate reader (Perkin-Elmer). All samples were done in duplicates for
each experiment.

3.3.10 Statistical analysis
All quantitation carried out in this study was analyzed using one-way ANOVA.
Statistical significance (p<0.05) for all quantitation (n≥3 ± SEM) is indicated with an
asterisk (*).
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3.4 Results
In situ invasion of epithelial tumour cells relies on processes such as EMT and
cell migration 6,24-27. Therefore the development and characterization of chemotherapeutic
compounds that target different steps of metastasis, and in particular cell migration, may
play an important role in curtailing tumour-related death. We recently showed that the
tricyclic compound, TBE-31, is capable of inhibiting actin polymerization

19

, however,

the mechanism(s) that this compound utilizes to inhibit cell migration has not been fully
characterized. We therefore set out identify TBE-binding proteins using various control
and biotinylated tricyclic compounds (Figure 3.1A).

3.4.1 TBE-31 binds to tubulin directly
To identify TBE-56-binding proteins, we incubated cell lysates with biotin, a nonbiotinylated derivative of TBE-31, TBE-55 (control), or TBE-56 (a biotinylated
derivative of TBE-55), followed by precipitation with NeutrAvidin beads (Figure 3.1B).
The TBE-56-bound proteins were separated on SDS-PAGE, processed and analyzed by
mass spectrometry (Figure 3.1B).

Although we previously identified several TBE-

binding proteins using this approach 19, this new analysis extended the identification of
novel cytoskeletal binding partners, including myosin-9, alpha-actinin, zyxin, and
vimentin (Figure 3.1C).

However, the largest number of peptides identified in the

analysis corresponded to alpha and beta tubulin—the basic building blocks of
microtubules. This therefore led us to investigate this interaction in greater detail through
immunoblotting analysis. Briefly, Rat2 lysates were incubated with DMSO, TBE-55 or
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Figure 3.1 Tricyclic compounds directly associate with tubulin
A) Structures of the triterpenoid and tricyclic compounds used in the study.
B) Rat2 fibroblast lysates were incubated with 10 µM biotin, TBE-55 or TBE-56 at 4°C
for 2h, followed by incubating with NeutrAvidin beads for 1h at 4°C to precipitate the
proteins interacting with TBE-56. SDS-PAGE and silver staining were performed and the
bands that were uniquely stained in the TBE-56-precipitated sample were excised from
the gel, trypsinized and analyzed by electrospray mass spectrometry. Dashes indicate the
bands that were analyzed.
C) Table of proteins identified to precipitate with TBE-56. The predicted molecular
mass, identification, protein coverage, and number of peptides that were present in the
analysis are shown. Note that tubulin was present in multiple bands from the analysis
(indicated in boxes).
D) Rat2 cell lysates (left panel) or purified tubulin protein (right panel) were incubated
with 10 µM TBE-55 (control) or 10 µM TBE-56 (biotinylated TBE) at 4°C for 2h,
followed by incubating with NeutrAvidin beads for 1h at 4°C to precipitate the proteins
interacting with TBE-56. The beads were then washed, subjected to SDS-PAGE and
immunoblotted with anti- beta (β) tubulin antibodies. The migration of tubulin is
indicated on the left of each panel.
E) Rat2 cell lysates were incubated with 0.1% DMSO (−), 10 µM biotin, 10 µM TBE-55
(control) or 10 µM TBE-56 (biotinylated TBE) at 4 °C for 2 h, followed by incubating
with NeutrAvidin beads for 1 h at 4 °C to precipitate proteins interacting with TBE-56.
The beads were then washed, subjected to SDS-PAGE and immunoblotted with antibetatubulin (α-beta-tubulin) or anti-EB1 (α-EB1) antibodies. The migration of tubulin or EB1
is indicated on the left of each panel.
F) Competitive binding studies were carried out similarly to the experiments described in
Panel D. Additional samples were added that had been preincubated with the indicated
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concentrations of TBE-31 or TBE-55, before incubating with TBE-56. Shown here is a
representative immunoblot for tubulin.
G) Purified tubulin (1 µg/ml) was incubated with 10 µM TBE-56 as described in panel A.
Additional samples were added that had been preincubated with the indicated
concentrations of biotin or TBE-31 before incubating with TBE-56. Shown here is a
representative immunoblot for beta-tubulin.
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TBE-56, precipitated with NeutrAvidin beads, processed for immunoblotting and probed
with tubulin antibodies (Figure 3.1D). As expected, we observed that TBE-56 associated
strongly with tubulin in cell lysates, whereas the negative TBE-55 control did not (Figure
3.1D, left panel). To assure that the TBE-tubulin interaction was not occurring through a
secondary protein (for example a microtubule +TIP protein) we repeated the experiment
and immunoblotted the precipitated TBE-56 for the presence of the +TIP protein, EB1
(Figure 3.1E).

We observed that tubulin, but not EB1, associated with TBE-56.

Furthermore, we also assessed TBE-56 association with purified tubulin, and observed
results similar to our cell lysate studies (Figure 3.1D, right panel), suggesting that the
interaction between TBE-56 and tubulin is indeed direct and not through an intermediate
binding partner. Finally, we carried out competitive binding assays to assess if the
parental TBE-31 compound could compete with the TBE-56-tubulin interaction (Figure
3.1F). Briefly, cell lysates were pretreated with either DMSO, or increasing
concentrations of TBE-31 or TBE-55, before performing TBE-56 pull-downs. We found
that by increasing the concentrations of TBE-31 or TBE-55 in the pretreatment, tubulin
was hindered from precipitation by TBE-56 in a dose-dependent manner (Figure 3.1F),
suggesting that TBE-31 itself is indeed able to associate with tubulin. To confirm that
TBE-31 associates with tubulin directly, we repeated these experiments using purified
tubulin and observed similar results (Figure 3.1G). Having found that tricyclic compound
TBE-31 associates with tubulin, we next assessed if TBE-31 would have an effect on
tubulin polymerization and/or the cellular microtubule network.
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3.4.2 TBE-31 alters microtubule organization and dynamics
We first investigated the ability of TBE-31 to inhibit tubulin polymerization in
vitro (Figure 3.2A). In the presence of either the vehicle (DMSO) or TBE-31, tubulin
was able to fully polymerize within one hour of incubation. That is, TBE-31 does not
alter in vitro tubulin polymerization. As positive and negative controls, we also assessed
tubulin polymerization in the presence of either nocodazole or paclitaxel, bona fide
depolymerizing and stabilizing agents, respectively. As expected, tubulin was unable to
polymerize in the presence of nocodazole and the rate of polymerization was increased in
the presence of paclitaxel (Figure 3.2A). Finally, as another control, we assessed in vitro
tubulin polymerization in the presence of the pentacyclic compound, CDDO-Im. Since
we had previously demonstrated that this compound interferes with microtubule
dynamics in cells, we expected that CDDO-Im would alter in vitro tubulin
polymerization (Figure 3.2A).

Interestingly, this did not occur (Figure 3.2A) and

therefore raises the possibility that triterpenoid and/or tricyclic compounds may alter
microtubule

dynamics

in

cells

but

not

via

the

rate

of

tubulin

polymerization/depolymerization directly. Thus, we attempted to assess the ability of
TBE31 or CDDO-Im to alter tubulin depolymerization in cells.
We assessed microtubule depolymerization by subcellular fractionation studies in
drug treated cells by isolating the polymerized cytoskeleton from the soluble monomers
14,21

.

After

subjecting

cytoskeletal

or

soluble

fractions

to

SDS-PAGE

and

immunoblotting, we observed that tubulin remained in the polymerized cytoskeletal
fractions in DMSO, CDDO-Im or TBE-31-treated cells (Figure 3.2B). However, when
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Figure 3.2 TBE-31 inhibits microtubule dynamics independent of tubulin
polymerization.
A) Purified tubulin was polymerized in the presence of 10 µM TBE-31, 10 µM CDDOIm, 3 μM paclitaxel, or 3 μM nocodazole as described in Materials and Methods. Tubulin
polymerization was measured and graphed as the change in fluorescence intensity
(arbitrary units) over time (min).
B) Mv1Lu cells were incubated in DMSO (vehicle), 1 µM TBE-31, 1 µM CDDO-Im, or
10 µM nocodazole (Nocod.; positive control) for 2 h at 37°C and then subjected to lysis
at 37 °C to separate soluble proteins (S) from the cytoskeleton (C). The subcellular
fractions were then subjected to SDS-PAGE analysis followed by immunoblotting for
tubulin.
C) Subconfluent Mv1Lu cells were grown on coverslips and incubated in either DMSO,
2 µM TBE-31, or 2 µM CDDO-Im for 2 h at 37°C. The cells were then fixed
permeabilized and immunostained with monoclonal tubulin antibody (green) and DAPI
(blue) for the nuclei. Shown here are representative immunofluorescence images taken
with an Olympus IX81 microscope at 60x magnification. The insets highlight the
organization of the microtubule network. Bar = 10 µm.
D) Subconfluent Mv1Lu cells transiently expressing GFP-EB1 were incubated in either
DMSO or 2 µM TBE-31 and imaged using an Olympus IX81 fluorescent microscope
equipped with a cell chamber. GFP-EB1 mobility was visualized over 2.5 min. The
starting point of EB1 comet movement (top panels) is shown. Insets were magnified to
visualize comet tail morphology (middle panels). Comet tail migration over 2.5 min. was
visualized (colored lines in bottom panels) and the track lengths were measured and
graphed. Shown are the mean ± SEM (n=3). Blue to red color bar represents shorter to
longer tracks, respectively.
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cells were incubated with the microtubule-depolymerizing agent, nocodazole, the
majority of the tubulin segregated with the soluble cellular components (Figure 3.2B).
Although these results were consistent with the in vitro assays, we continued our analysis
of TBE-31 or CDDO-Im on microtubule dynamics because of the crucial role that the
microtubule network plays in cell migration by providing a cellular structure as well as a
network for vesicular trafficking 7,8,11.
We examined the cellular microtubule network by assessing the general
morphology using immunofluorescence microscopy. Briefly, Mv1Lu cells were treated
with DMSO, TBE-31, or CDDO-Im, and immunostained with a tubulin antibody to
visualize the microtubule network. In the DMSO-treated cells, microtubules emanated
from the microtubule-organizing center (MTOC) in a straight and linear fashion, while
the CDDO-Im demonstrated a high degree of curvature and a tortuous pattern, which is
consistent with our previous findings (14; Figure 3.2C). Interestingly, the microtubule
organization in TBE-31 treated cells was observed to be in a crosshatched pattern, that
was distinct from DMSO and CDDO-Im treated cells (Figure 3.2C). Together these
results suggest that TBE-31 alters the organization of the microtubule network, but not
necessarily the rates of growth or retraction. We furthered our investigation by next
examining microtubule-dependent dynamics.
End binding protein 1 (EB1) localizes to the microtubule plus ends where it
modulates their dynamics and interaction with organelles

11,28,29

. We assessed the rate of

microtubule growth as well as the microtubule persistence by transfecting GFP tagged
EB1 in Mv1Lu cells and visualizing them over time to observe microtubule dynamics in
the presence of our compounds (Figure 3.2D). In DMSO treated control cells, we
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observed that EB1-labeled ends of growing microtubules gave the appearance of rapidly
growing oval (longer tail) comet-like streaks that radiated outwards smoothly from the
MTOC in an organized and structured manner (Figure 3.2D; Video 3-1). However, TBE31 treated cells demonstrated shorter, rounded comet-like streaks, consistent with slower
growing microtubules 30. Furthermore, close examination of movies gave the appearance
of multiple MTOCs in TBE-31 treated cells, whereas a single major MTOC was observed
in control cells. This multi-MTOC and overall less organized movement pattern was
consistent

with

the

cross-hatched

microtubule

pattern

demonstrated

in

the

immunofluorescence microscopy analysis (Figure 3.2D; Video 3-2). To confirm that the
EB1 tracks were less organized in the TBE-31-treated cells we carried out quantitation
and observed that the EB1 tracks in DMSO treated cells averaged 8.5± 1 µm/track,
whereas TBE-31-treated cells contained significantly shorter EB1 tracks, averaging 5.8 ±
0.6 µm/track (Figure 3.2D, bottom graph).

3.4.3 TBE-31 disrupts microtubule-dependent trafficking
Having shown that TBE-31 affects microtubule organization and dynamics, we
sought to investigate processes that are dependent on proper microtubule function; the
positioning of the early endosome compartment to the peri-nuclear region of the cell. In
brief, Mv1Lu cells were incubated in media containing DMSO, 1 μM TBE-31, or 1 μM
CDDO-Im for 2h at 37°C. The cells were then immunostained with early endosome
antigen 1 (EEA1) antibody for the early endosome and DAPI for the nuclei (Figure
3.3A). We then scored the number of cells that demonstrate a peri-nuclear staining
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Video 3-1 and 3-2 EB-1 Movies
Subconfluent Mv1Lu cells transiently expressing GFP-EB1 were incubated in either
DMSO or 2 µM TBE-31 and imaged using an Olympus IX81 fluorescent microscope
equipped with a cell chamber. GFP-EB1 mobility was visualized over 2.5 min.
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Figure 3.3 TBE-31 affects trafficking and cellular distribution of EEA1-positive
endosomes
A) Subconfluent Mv1Lu cells were grown on coverslips and incubated in DMSO, 1 µM
TBE-31, or 1 µM CDDO-Im for 2 h at 37°C. The cells were then fixed permeabilized and
immunostained with EEA1 antibody (green) for the early endosome and DAPI (blue) for
the nuclei. Shown here are representative immunofluorescence images taken with an
Olympus IX81 microscope at 60x magnification. The insets highlight the early endosome
compartments. Bar = 10 µm.
B) Immunofluorescence microscopy was carried out as described in panel A and the
number of cells with peri-nuclear EEA1 staining was quantitated and graphed. Shown
are the mean ± SEM (n=3; * P≤0.05).
C) Mv1Lu cells stably expressing HA-tagged type II TGFβ receptors (TβRII) were
incubated at 4 °C with anti-HA antibodies, followed by Alexa555-labelled secondary
antibodies (red). The cells were then incubated at 37 °C in the absence (top panel;
Control) or presence of 1 µM TBE-31 (middle panel) or 1 µM CDDO-Im (bottom panel)
for 1 h. Cells were then fixed, permeabilized, and immunostained with anti-EEA1
(EEA1; green) antibodies. Areas of interest (insets) are magnified and are shown below
each panel. The contour (dotted line) of each cell was added to indicate the relative
position of TβRII and EEA1 from the cell periphery. Bar = 10 µm.
D) Immunofluorescence microscopy was carried out as described in panel C and the
number of cells with peri-nuclear TGFβ receptor staining was quantitated and graphed.
Shown are the mean ± SEM (n=3; * P≤0.05).
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pattern versus cells with a dispersed EEA1 staining pattern. In the DMSO treated cells
80.7 ±1.0% of the cells displayed peri-nuclear staining, whereas TBE-31 and CDDO-Im
treated cells displayed only 60.3 ±1.3% and 39.4 ±0.6% peri-nuclear staining,
respectively (Figure 3.3B). We next examined what implications this may have on
endocytosis and protein trafficking. To do so, we used the well-characterized
transforming growth factor beta (TGFβ) receptor (TGFβR) model that utilizes
microtubules to deliver TGFβRs to the early endosome 31.
Cell surface TGFβRs, undergo endocytosis and traffic to the early endosome
where they can interact and phosphorylate Smad proteins to propagate TGFβ signaling
23,32,33

. To evaluate the ability of TGFβR microtubule-dependent trafficking to the early

endosome, we used an immunofluorescence microscopy based approach. Briefly, cells
stably expressing HA-tagged type II TGFβR (TβRII) were treated with DMSO, TBE-31
and CDDO-Im and then incubated at 4°C to inhibit endocytosis and to allow the labeling
of cell surface receptors. The cells were then incubated at 37°C which reinitiated receptor
endocytosis and trafficking to the early endosome. We then performed standard
immunofluorescence microscopy and probed for EEA1 to visualize the early endosome
in addition to the previously labeled TGFβR. We observed that TGFβRs in vehicle
(DMSO)-treated cells internalized and co-localized to EEA1-positive vesicles in the perinuclear region of the cell (Figure 3.3C).

Interestingly, TBE-31 or CDDO-Im cells

demonstrated less peri-nuclear trafficking of TGFβRs, however the receptors still colocalized with EEA1-positive vesicles near the cell periphery (Figure 3.3D). Taken
together, our results suggest that TBE-31 alters microtubule dynamics, and impairs

132

protein trafficking—two processes that are important in cell polarity and migration

7-11

.

As such, we next sought to explore the effects of TBE-31 on these processes.

3.4.4 TBE-31 alters front-rear polarity in migrating cells
Cell migration is dependent on the proper localization of proteins involved in
maintaining cell polarity (for e.g., Rac1 and IQGAP1)

8-10,34-36

, which are dependent on

early endosome trafficking (Rab5 positive vesicles for Rac1)

11-13

. We previously

demonstrated that CDDO-Im displaces IQGAP1, and Rac1 from the leading edge of
migrating Rat2 fibroblasts and inhibits cell migration

14,15

. Here we examined if the

effects of TBE-31 on the microtubule network and protein trafficking would also lead to
impaired cell polarity. Delivery of Rac1 has been shown to be dependent on Rab5
function, so Rab5 vesicles were examined in a similar manner as our analysis of the
EEA1 compartment. However, Rab5 distribution in TBE-31-treated cells was similar to
that of control cells (treated with DMSO), while CDDO-Im treated cells did exhibit a
higher degree of Rab5 vesicle placement near the cell periphery (Figure 3.4).
We next examined the localization of IQGAP1 and Rac1 in migrating cells
(Figure 3.5). Briefly, Rat2 fibroblasts were grown to confluence before an artificial
wound was introduced by scratching the cells. The cells were allowed to polarize for 4h
before being treated with DMSO, TBE-31 or CDDO-Im. Following immunostaining for
IQGAP1 and Rac1, the cells were processed for immunofluorescence microscopy (Figure
3.5A). We observed that 66.9 ± 5.8% of the cells treated with DMSO were elongated and
had IQGAP staining at the leading edge—a phenotype indicative of proper polarization
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Figure 3.4 TBE-31 does not affect cellular distribution of Rab5-positive endosomes
Subconfluent Mv1Lu cells were grown on coverslips and incubated in 0.1% DMSO, 1
µM TBE-31, or 1 µM CDDO-Im for 2 h at 37°C. The cells were then fixed permeabilized
and immunostained with Rab5 antibody (green) for the early endosome and DAPI (blue)
for the nuclei. Shown here are representative immunofluorescence images taken with an
Olympus IX81 microscope at 60x magnification. The insets highlight the early endosome
compartments. Bar = 10 µm.
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Figure 3.5 TBE-31 alters cell polarity
A) Confluent monolayers of Rat2 fibroblasts were scratched and incubated at 37°C in
DMEM supplemented with 10% FBS for 4 hours to allow them to polarize. Cells were
then incubated for 2 h in media containing DMSO, 1 µM TBE-31, or 1 µM CDDO-Im.
The cells were then fixed, permeabilized and immunostained with monoclonal Rac1
antibody (green), polyclonal IQGAP1 antibody (red) and DAPI (blue) for the nuclei.
Shown here are representative immunofluorescence images taken with an Olympus IX81
microscope at 40x magnification. Bar = 10 µm.

B) Immunofluorescence microscopy was carried out as described in panel A and the
number of cells containing an elongated morphology and one IQGAP1-positive leading
edge, cells containing multiple IQGAP1-positive protrusions or cells lacking IQGAP1
staining at the cell surface were quantitated and graphed. Shown are the mean ± SEM
(n=3; * P≤0.05).
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and migration. In contrast, only 36.1 ± 4.1% of CDDO-Im-treated cells demonstrated
proper polarization (Figure 3.5B). Furthermore, the majority, 49.7 ± 1.0 %, of CDDOIm-treated cells showed no elongation, as well as an absence of IQGAP1 from the
leading edge, which is consistent with our previous findings

14

. TBE-31 was also

observed to affect polarity, with only 42.0 ± 5.3% of cells showing IQGAP1 localization
at the leading edge. Interestingly, unlike CDDO-Im or DMSO treated cells, TBE-31
treated cells exhibited IQGAP1 localization at multiple areas around the cell periphery,
causing the formation of multiple protrusions in 43.5 ± 2.5% of cells (Figure 3.5B).
The observation that TBE-31 induced multiple Rac1/IQGAP-positive protrusions
in cells prompted us to investigate whether these protrusions contained active Rac1. We
therefore examined the multiple protrusions in the TBE-31 cells using an active-Rac1
antibody that only recognizes Rac1 when it is in its GTP-bound form (Figure 3.6A) The
experimental design was similar to the one described above: A monolayer of cells were
scratched and allowed to polarize before treating with various compounds. The cells were
then immunostained with Rac1 and anti-active Rac1-GTP. In the DMSO control, Rac1 at
the single protrusions co-localized with active-Rac1-GTP. Interestingly, TBE-31-induced
multiple protrusions contained active (GTP-bound) Rac1 (Figure 3.6B), thus confirming
that the Rac1 was indeed active in multiple regions of TBE-31 treated cells. To further
confirm that cellular regions that were labeled with the active-Rac1 antibody indeed
contained GTP-bound Rac1, we further analyzed if there was the Rac1 activator, Tiam1,
co-localization (Figure 3.6B). Indeed, we found co-localization of Tiam1 and activeRac1 in single protrusions of control cells, multiple protrusions in TBE-31 treated
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Figure 3.6 TBE-31 redistributes Rac1 activity to multiple areas of the plasma
membrane
A) Confluent monolayers of Rat2 fibroblasts were scratched and incubated at 37°C in
DMEM supplemented with 10% FBS for 4 hours to allow them to polarize. Cells were
then incubated for 2 h in media containing 0.1% DMSO, 1 µM TBE-31, or 1 µM CDDOIm. The cells were then fixed, permeabilized and immunostained with an antibody that
recognizes GTP-bound Rac1 (Active-Rac1; green), a Rac1 antibody (Rac1; red) and
DAPI (blue) for the nuclei. Shown are representative immunofluorescence images. Areas
of interest (insets) are magnified and are shown below each panel. Bar = 10 µm.

B) Confluent monolayers of Rat2 fibroblasts were scratched and incubated at 37°C in
DMEM supplemented with 10% FBS for 4 hours to allow them to polarize. Cells were
then incubated for 2 h in media containing DMSO, 1 µM TBE-31, or 1 µM CDDO-Im.
The cells were then fixed, permeabilized and immunostained with a polyclonal antibody
that recognizes GTP-bound Rac1 (Active-Rac1; green), a monoclonal Tiam1 antibody
(Tiam1;

red)

and

DAPI

(blue)

for

the

nuclei.

Shown

are

representative

immunofluorescence images. Areas of interest (insets) are magnified and are shown
below each panel. Bar = 10 µm.
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cells, and a lack of membrane localization in CDDO-Im-treated cells (Figure 3.6B).
Taken together, our results suggest that TBE-31 can disrupt the front-rear polarity in
migrating fibroblasts, in a manner distinct from CDDO-Im. TBE-31 induces the
formation of multiple protrusions that contain active Rac1, whereas CDDO-Im reduces
active Rac1 localization at the membrane.

3.4.5 TBE-31 inhibits cell migration
A single dominant leading edge is associated with directionally persistent intrinsic
cell migration, and enhanced directed cell migration

37

. Therefore multiple protruding

lamellipodia may result in random intrinsic migration and reduce the capacity for directed
cell migration. We therefore next sought to examine the effects of TBE-31 on directed
cell migration. In brief, a confluent monolayer of Rat2 fibroblasts was scratched and
incubated in media containing either DMSO, varying concentrations of TBE-31, or
CDDO-Im. Bright-field images were taken with an inverted microscope at 0 h and 16 h.
The initial and final width of the scratch was measured, and the difference was calculated
to determine the distance migrated. We observed that with increasing concentrations of
TBE-31 or CDDO-Im the distance of migration decreased in a dose-dependent manner
(Figure 3.7A). More specifically, quantitation demonstrated that both compounds
exhibited similar inhibition of cell migration and above 0.75 μM, TBE-31 and CDDO-Im
were able to reduce cell migration by approximately 60.0 ± 7.7% and 86.0 ± 2.6%
percent, respectively (Figure 3.7B). CDDO-Im and TBE-31 have been previously shown
to induce apoptosis, albeit at higher concentrations 38. In order to assess if the decrease in
cell migration may be due to possible cytotoxic effects, we performed trypan blue
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Figure 3.7 TBE-31 inhibits cell migration.
A) Confluent monolayers of Rat2 fibroblasts were scratched and incubated at 37°C in
DMEM supplemented with 10% FBS, containing either DMSO, 1 μM TBE-31 or 1 μM
CDDO-Im for 16 h. Shown are representative brightfield microscopy images taken with
an Olympus IX81 microscope at 10x magnification at 0 and 16 h post-incubation.
B) Scratch assays were carried out as described in panel A with cells incubated with
increasing concentrations of TBE-31 or CDDO-Im. Relative cell migration was
quantitated using ImagePro software and graphed. Shown are the mean ± SEM (n=3;
*=P≤0.05).
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exclusion tests. We found that TBE-31 nor CDDO-Im was cytotoxic up to concentrations
of 1.0 µM in Rat2 fibroblasts (data not shown). Furthermore, wash out studies indicated
that cells recover from CDDO-Im or TBE-31 incubation to fill in the gap (data not
shown).
Taken together, our results suggest that TBE-31 targets the microtubule cytoskeleton
and establishes multiple leading edges around migrating cells, which leads to decreased
cell migration.
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3.5 Discussion
We have previously demonstrated that TBE-31 targets linear actin polymerization to
alter cell morphology and inhibit cell migration 19. In this study we continued to examine
the effects of TBE-31 on cell migration with a focus on the microtubule network and
observed that TBE-31 binds to tubulin directly and disturbs the dynamics of the
microtubule network. Identifying the potential binding sites of TBE-31 on tubulin will
allow for the characterization of how this class of compound inhibits microtubule
dynamics. Based on previous studies, the interaction of triterpenoid and tricyclic
compounds with target proteins has been shown to occur via association with reactive
cysteine residues 38-42. We are currently assessing if this is the case of TBE-31 binding to
tubulin. Furthermore, studying the impact of TBE-31 on different microtubule-dependent
trafficking processes will be of great interest. Indeed, endocytosis and recycling play an
important role in the regulation of integrin turnover and redistribution—especially during
dynamic processes such as cell migration and invasion. The way in which focal adhesion
proteins are trafficked is also recognized to influence their function and dictate the
polarized distribution

43,44

. Finally, the multiple leading edges visualized in TBE-31-

treated cells begs the question if the effects are global or local. Is cell polarity preserved
and/or is there a defect in control of number of projections, without necessarily
eliminating polarity?

Addressing these questions will help identify the different

mechanisms that these chemopreventative multi-target drugs use to inhibit cell migration.
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Chapter 4

Acetylenic tricyclic bis-(cyano enone) interacts with
actin through cysteine-374 to interfere with actin
polymerization
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Chapter 4

4.1 Chapter Summary
The migratory and invasive potential of tumour cells relies on the actin cytoskeleton.
In the past we have demonstrated TBE-31 inhibits actin polymerization and here we
further examine the exact binding between TBE-31 and actin. We demonstrate that
iodoacetamide, a cysteine (Cys) alkylating agent, interferes with the ability of TBE-31 to
interact with actin. In addition, computational analysis identified Cys 217, Cys 272, Cys
285 and Cys 374 as potential TBE-31 binding sites. Using mass spectrometry analysis we
determined 1 molecule of TBE-31 binds with 1 molecule of actin. We mutated the
cysteines of actin to alanine and performed a pull-down analysis with a biotin labeled
TBE-31 and demonstrated that by mutating Cys 374 to Alanine the pull-down
significantly decreased association between TBE-31 and actin, suggesting that TBE-31
binds to Cys 374. A characterization of the eGFP-C374A-Actin in NIH3T3 cells showed
reduced stress fiber formation, suggesting Cys 374 is necessary for efficient
polymerization or incorporation into filamentous actin. Lastly, transwell migration assays
were conducted with NIH3T3 cells, and the number of cells that migrated through the
transwells was significantly reduced. Taken together or results suggest TBE-31 binds to
Cys 374 of actin to inhibit actin polymerization and may potentially be the mechanism
wherein TBE-31 utilizes to inhibits cell migration.
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4.2 Introduction
Cell migration is essential for numerous physiological processes such as
embryogenesis, immune response, cell differentiation, wound healing, and cell renewal.
However, it is also co-opted in the later stages of cancer

1-3

. During metastasis, tumour

cell migration and invasion are exploited to allow cells to disseminate to distant sites and
establish secondary tumours. Metastasis results in nearly 90% of cancer related deaths 4.
Cell migration begins with an initial protrusion of the plasma membrane. These
protrusions attach to the substratum through newly formed focal adhesions to provide
traction, while the mature focal adhesions at the rear or lagging end of the cell
disassemble to aid in retraction of the rear. As this process repeatedly occurs, the cell
translocates across the substratum

1-3

. The initial steps of cell migration rely on the

localization of polarity proteins to establish the front or leading edge of the cell and
promote reorganization of the cytoskeleton towards the direction of migration. The entire
cytoskeleton acts in concert for proper cell migration, but actin polymerization provides
the primary force for generating the cellular protrusions. The localization of Rac1 and
Cdc42 to the leading edge initiates signaling cascades to activate actin-binding proteins
and

stimulate

actin

polymerization.

Formin,

and

formin

homologs

increase

polymerization rates by facilitating monomer addition to the barbed end of actin
filaments and generally contribute to forming linear filamentous actin arrays

5,6

. During

cell migration, these linear or unbranched actin arrays form long, spike-like, protrusions
known as filopodia, which probe the environment and act as sensors

35,36,43

. In contrast,

Rac1 activates actin related proteins 2 and 3 (Arp2/3), promoting them to bind to preexisting actin filaments and act as additional sites of polymerization

7,8

. This generates a
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rapidly polymerizing branched array of actin, which allows formation of lamellipodia,
which are broad, fan-like, protrusions that drive the cell forwards 1-3,9.
The actin cytoskeleton is a potential target for tumour cell migration, an important
aspect of metastasis; however there are still no actin targeting compounds used in
chemotherapy

10,11

. We have previously demonstrated that TBE-31 binds to actin,

disrupts actin polymerization, and inhibits tumour cell migration 12. In this study we aim
at identifying the binding site(s) in actin implicated in interactions with TBE-31, thus
allowing a better understanding of its mechanism(s) for inhibiting actin polymerization.
TBE-31 contains αβ-unsaturated carbonyl groups in their A and C rings. These
functional groups suggest that TBE-31 may undergo Michael addition with nucleophilic
targets containing reactive sulfhydryl residues (Figure 4.1). Indeed, previous studies
demonstrated TBE-31 reacts directly with the sulfhydryl groups of dithiothreitol (DTT),
suggesting TBE-31 may interact with proteins through reactive cysteines

13-16

. Further

research, demonstrated spectroscopically that both the cyano enone functions on ring A
and C of TBE-31 react with cysteine residues in Keap1, resulting in the transcriptional
activation of cytoprotective genes

15,17,18

. However, no specific cysteine residue(s) were

identified in those studies. With these previous findings in mind, we hypothesized TBE31 interacts with the cysteine residues of actin. In this study we use in silico docking
simulations, mass spectrometry and mutational analyses approaches to determine that
cysteine 374 on actin is an important contributor of its interactions with TBE-31.
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Figure 4.1 TBE-31 proposed mechanism of interaction with cysteines
The αβ-unsaturated carbonyl groups (highlighted in red) undergo Michael addition
reaction with the sulfhydryl groups (SH) of cysteines forming covalent adducts

156

4.3 Materials and Methods
4.3.1 Cell Culture, Antibodies and Reagents
Rat2 and NIH 3T3 fibroblasts were cultured in Dulbecco’s modified Eagle’s
Medium (DMEM). Both cell lines were cultured in a 37°C humidified incubator with 5%
CO2, and medium was supplemented with 10% fetal bovine serum (FBS) unless
otherwise stated.
AlexaFluor 555-conjugated phalloidin (A34055) and anti-GFP antibodies (for
immunofluorescence) (A6455) were purchased from Invitrogen. NeutrAvidin Agarose
beads (29200) were purchased from Thermo Scientific. Anti-GFP (632381) for
immunoblotting was purchased from Clonetech. Iodoacetamide was purchased from
Bioshop (#IOD 500). Polyjet for transfection was purchased from FroggaBio
(SL100688). CDDO-Im and TBE-31 compounds were provided by Dr. Michael B. Sporn
(Dartmouth, NH). The plasmid encoding eGFP-Actin was a generous gift from Dr. Lina
Dagnino (University of Western Ontario, ON, Canada).

4.3.2 Affinity Pull-downs
One mg of Rat2 protein lysates in 1 ml were incubated with 10 μM TBE-56
(biotinylated TBE-31 or b-TBE-31) at 4°C for 16 h, followed by incubating with 25 μl of
NeutrAvidin beads for 1 h at 4°C to isolate the proteins interacting with the biotin
conjugate. Afterwards, the beads were thoroughly washed, and 30 μl of 2X Laemmli
sample preparation buffer was added. These samples were then subjected to denaturing
polyacrylamide gel electrophoresis, and transferred to membranes that were probed with
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anti-actin or anti-GFP antibodies. For studies utilizing iodoacetamide to block cysteines
before pulldown analysis, the lysates were incubated with various concentrations of
iodoacetamide for 4h on ice before incubating with TBE-56 and proceeding as above. For
studies isolating the eGFP-Actin and the cysteine to alanine mutants, the plasmids were
transfected into Rat2 cells for 24h before lysis. It was necessary in these experiments to
include 1M Tris-Cl in the lysis buffer to ensure all samples contained monomeric actin
irrespective of which individual cysteine to alanine mutant was analyzed.

4.3.3 Computational Analysis
The crystal structure of a complex between actin and cytochalasin D was obtained
from the protein data bank (PDB code 3EKS)

19

. Cytochalasin D was removed and

docking simulations were carried out using SwissDock 20. All cysteines were assessed to
verify if they are solvent exposed and the number of binding sites for TBE-31 and their
affinities were recorded (appear as ΔG).

4.3.4 Mass Spectrometry Analysis
Actin purified from human platelets was purchased from Cytoskeleton Inc
(aphl99). This actin incubated with either 50-fold molar excess of TBE-31,
iodoacetamide or the equivalent volume of DMSO, and was processed for mass
spectrometry analysis. Mass spectra were generated using a QTof Micro mass
spectrometer (Waters) equipped with a Z-spray source and run in positive ion mode with
an Agilent 1100 HPLC used for LC gradient delivery. For LC-MS/MS, the protein was
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cleaved with either trypsin or chymotrypsin and analysis in MASCOT combined both set
of fragments to improve overall coverage of the protein.

4.3.5 Mutagenesis
Cysteine (C) residues in eGFP-labelled human actin (Addgene) were mutated to alanine
(A) using the Quickchange mutagenesis kit (Agilent Technologies) according to
manufacturer guidelines. All mutants were transformed into a XL1 Blue strain of
Escherichia coli, amplified, purified by the Qiagen Miniprep Kit (Qiagen), and their
sequences were verified at the London Regional Genomics Centre (London, ON,
Canada).

4.3.6 Immunofluorescence microscopy
In all immunofluorescence microscopy studies, cells were fixed in 4%
paraformaldehyde for 10 min, permeabilized in 0.25% Triton X-100 for 5 min, blocked in
10% FBS, and immunostained overnight with the appropriate primary antibodies. All
images were taken with an Olympus IX81 inverted epifluorescence microscope.
Quantitations for cells with actin stress fibers were quantitated into three categories,
strong stress fibers, weak stress fibers, and none. Quantitations were carried out in the
green channel for GFP.

159

4.3.7 Transwell cell migration assays.
NIH3T3 cells were transfected with equal amounts of plasmids encoding either
the eGFP-Actin or eGFP-Actin-C374A. After 24h, the cells were serum starved for 4h
prior to being seeded onto the top of a Transwell chamber (Costar). A total of 50,000
cells per condition were seeded and allowed to migrate toward the bottom chamber,
which contained medium supplemented with 10% serum for 18h. The upper and lower
chamber also contained either DMSO (vehicle) or TBE-31 (0.5 μM). In parallel, 50,000
cells from each condition were seeded onto coverslips in medium containing 10% serum
to monitor transfection efficiency, or in serum free medium containing either DMSO or
0.5 μM TBE-31, to monitor cell viability. After 18 h, the cells on the upper side of the
Transwell membrane were removed with a cotton swab, and the cells that had migrated
through the insert (i.e. on the underside of the Transwell membrane) were fixed with 4%
paraformaldehyde. Cells on both the Transwell membrane and coverslips were stained
with DAPI (4′,6′-diamidino-2-phenylindole) and mounted onto glass slides. Images were
acquired using an IX81 inverted microscope (Olympus). Ten representative fields were
acquired at ×100 magnification (approximate field of view of 59, 000 μm2) and
quantified by counting the blue nuclei, or green fluorescent cells.

4.3.8 Statistical analysis
All quantitation carried out in this study was analyzed using one-way ANOVA.
Statistical significance (p<0.05) for all quantitation is indicated with an asterisk (*).

160

4.4 Results
4.4.1 Iodoacetamide interferes with TBE-31 binding to actin
TBE-31 has been suggested to interact with proteins through cysteine residues via
a Michael addition 14,17. To verify whether this is true of actin, we used iodoacetamide—a
cysteine alkylating agent—to pretreat lysates before using in pull-down assays to assess if
there would be an effect on TBE-31 binding to actin. In brief, Rat2 lysates were
incubated with increasing concentrations (1-10 mM) of iodoacetamide, prior to a
subsequent incubation with biotin labeled TBE-31 (TBE-55) and drug-bound complexes
were isolated using NeutrAvidin-agarose beads. The samples were then processed for
SDS-PAGE, and transferred to membranes that were probed for actin (Figure 4.2A).
Concentrations of iodoacetamide of 5 mM and 10 mM significantly inhibited the pulldown of actin by the biotin labeled TBE-31 by 50.64 ± 9.68% (P≤0.01) and 66.50 ±
8.87% (P≤0.001) respectively (Figure 4.2B), thus supporting the notion that TBE-31
binds to actin through cysteine thiol groups.

4.4.2 TBE-31 is predicted to bind to cysteines using computer
simulation analyses
To complement the above findings, we next sought to use computational
simulation of the potential cysteines in actin that TBE-31 was likely to bind. SwissDock
(Swiss Institute of Bioinformatics)
structure of actin (3EKS)

19

20

was used to model TBE-31 binding to the crystal

acquired from the protein databank (PDB) server. The actin

structure was originally determined from actin crystalized in the presence of
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Figure 4.2 Iodoacetamide interferes with TBE-31 binding
A) Rat2 fibroblast lysates were incubated with a 0-10 mM iodoacetamide for 1h, and then
incubated with 10 µM biotin labeled TBE-31 (TBE-56) overnight before precipitating
with NeutrAvidin-agarose beads. The samples were then subjected to SDS-PAGE and
immunoblotted for Actin. Shown are representative immunoblot (n=3).
B) Experiments carried out as described in Panel A were quantitated and graphed by
dividing the amount of Actin pulled-down relative to the iodoacetamide free control.
Error bars represent the mean +/- SEM. **P< 0.01, *** P<0.001.
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cytochalasin D (a bona fide actin depolymerizing agent), however for our analysis the
cytochalasin D was removed. Of the > 40 potential TBE-31-actin interacting regions, the
majority of the putative binding sites were predicted to reside in the same cleft that is
targeted by cytochalasin D.

More importantly, association of TBE-31 in this cleft

positions this drug to interact with Cys 374, at the C-terminus of actin (Figure 4.3A).
Other potential cysteines include Cys 217, Cys 272, and Cys 285, with binding affinities
calculated to be ΔG -7.5, ΔG -6.8, ΔG -6.3 and ΔG -6.2 kcal/mol respectively (Figure
4.3B and 4.3C). With these potential targets in mind, we next sought to verify which
cysteines were important for TBE-31 binding using a mass-spectrometry approach and
mutational pull-down analyses.

4.4.3 Mass Spectrometry

Analysis

We previously showed TBE-31 interacting with purified actin through an in vitro
pulldown approach

12

. Although the actin preparation used in this approach was 99%

pure, there is a possibility that the interaction of TBE-31 and actin may occur through an
intermediate actin-binding protein. We therefore attempted to assess if TBE-31 binding to
actin was direct and if so, determine the stoichiometry of the interaction. In brief, purified
actin was incubated with a 50-fold molar excess of, TBE-31, iodoacetamide as a positive
control and an equivalent volume of DMSO as a vehicle control. Afterwards, the samples
were subjected to Liquid Chromatography Mass Spectroscopy analysis (LC-MS), and the
average masses of the complexes analyzed were measured. The average
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Figure 4.3 Modelling TBE-31 interaction with actin
A) Cytochalasin D bound Actin PDB file (3EKS) (right image) was used in SwissDock to
model binding sites between TBE-31 and actin (left image)
B) Actin PDB file (3EKS) with TBE-31 bound, and cysteines highlighted
C) Summary of information for the cysteines on actin
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mass of actin (Figure 4.4A) was determined to be 41661.52 ± 0.91 Da. The
iodoacetamide treated samples (Figure 4.4C) contained additional species at molecular
masses of 41719.56 ± 0.21 Da and 41776.32 ± 0.75 Da, which correspond to the addition
of one (+57 Da) or two (+114 Da) iodoacetamide molecules after forming a Michael
addition. Similarly, incubation with TBE-31 (Figure 4.4B) resulted in the appearance of a
species with molecular mass of 41992.39 ± 0.64 Da (+330.38 Da), which corresponds to
the addition of one molecule of TBE-31. These results confirm that TBE-31 binds to
actin, and the presence of only one shifted molecular mass peak suggests that only one
molecule of TBE-31 binds to one molecule of actin.
We next sought to determine which cysteine TBE-31 is interacting with. Purified
actin was incubated with DMSO, and TBE-31 as above, and then digested with trypsin or
chymotrypsin. The fragment sizes were determined by tandem Mass Spectroscopy (MSMS) and the data were analyzed to find fragments with an increase in mass corresponding
to the molecular weight of TBE-31. By combining the predicted fragments from the
chymotrypsin and trypsin analyses, the overall coverage for actin (Figure 4.5A) was
greater than 90%. However, although the overall coverage was high, fragments
containing the surface exposed cysteines were relatively underrepresented. Indeed, there
were only two fragments containing the last cysteine (Cys 374; Figure 4.5B). Since this
analysis yielded inconclusive results and any potential binding sites observed in TBE-31shifted actin fragments were also observed in the DMSO control, it was necessary to
develop another method to determine which cysteine(s) on actin were responsible for
interacting with TBE-31.
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Figure 4.4 Mass Spectrometry analysis reveals TBE-31-Actin interaction
A) Mass of actin protein after incubation with DMSO as determined by liquid
chromatography followed by mass spectrometry.
B) Mass of actin protein after incubation with 50-fold molar excess TBE-31 as
determined by liquid chromatography followed by mass spectrometry.
C) Mass of actin protein after incubation with 50-fold molar excess iodoacetamide as
determined by liquid chromatography followed by mass spectrometry.
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Figure 4.5 LC-MS/MS analysis of TBE-31-actin interaction
A) Sequence coverage (blue) of actin (grey) after incubation with 50-fold molar excess
TBE-31 or DMSO vehicle control, obtained by LC-MS/MS merged analysis of the
peptide mixture obtained after separate trypsin and chymotrypsin digest.
B) Cropped view of analysis from above to highlight the cysteines.
C) Legend for post-translational modifications, with TBE-31 highlighted in red
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4.4.4 Mutation of cysteine-374 interferes with TBE-31 binding to
actin
A series of vectors encoding actin forms with cysteine to alanine mutation at
positions 217 (C217A), 257 (C257A), 272 (C272A), 285 (C285A), and 374 (C374A)
were generated, which includes all but one of the cysteines in actin. Based on our above
analysis, double mutants were also generated at cysteine 272 and 374 (C272A/C374A);
and cysteine 285 and 374 (C285A/C374A; Figure 4.6A). Each plasmid was sequenced to
verify the intended mutations were present. These vectors were then transfected into Rat2
fibroblasts, and cell lysates were processed for pull-down analyses (Figure 4.6B) as done
previously

12

. Using this approach, we observed that significantly less (60.61±9.02%)

C374A actin associated with the biotinylated-TBE-31, compared to the wild-type actin
control (Figure 4.6C). Similarly, actin containing double cysteine mutants (that had
C374A mutation in common) showed a comparable reduction as the single C374A
mutant, thus suggesting that cysteine 374 is important for actin interaction with TBE-31.

4.4.5 Cysteine-374 is necessary for efficient actin polymerization
We next characterized actin containing the cysteine-374 mutation.

We first

assessed its ability to contribute to stress fibers in migrating cells. In brief, eGFP-Actin,
eGFP-Actin-C257A, eGFP-Actin-C272A or eGFP-Actin-C374A was overexpressed in
NIH3T3 cells, fixed and probed with phalloidin and anti-GFP antibodies. Using
immunofluorescence imaging we observed robust stress fibers in the eGFP-Actin WT or
mutant overexpressing cells (Figure 4.7A). Indeed, the eGFP-Actin was incorporated into
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Figure 4.6 Cysteine to alanine mutation on cysteine 374 interferes with TBE-31
interaction
A) Schematic of eGFP-Actin (top), and the cysteine (C) to alanine (A) mutants generated
B) Rat2 fibroblasts were transfected with the indicated plasmids and lysed. One
milligram of lysate then incubated with 10 µM of biotin labeled TBE-31 (TBE-56) for
16h before being pulled-down with NeutrAvidin-agarose beads. The samples were then
processed and subjected to SDS-PAGE and immunoblotted for green fluorescent protein.
Shown here are representative immunoblots (n=5).
C) Quantitations of the above experiments were carried out by dividing the amount of
GFP-Actin pull down by the input and expressed as a relative amount compared to the
WT pulldown (n=5). Error bars represent SEM. **P<0.01.
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Figure 4.7 eGFP-C374A-actin demonstrates poor stress fiber incorporation
A) NIH3T3 cells were transfected with GFP-Actin, or GFP-Actin-C374A. After 48h the
transfected cells were processed for immunofluorescence imaging and probed with
phalloidin (red) for actin stress fibers, and anti-GFP (green) for GFP. Scale bars represent
10 microns.
B) Quantitation of experiments carried out as described in Panel A were carried out for
cells containing either strong, weak or no stress fibers. GFP-ActinC257A, and GFPActin-C272A were included as controls. Errors bars represent the mean ± SEM. P<0.001
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the stress fibers, indicating that overexpression of actin did not alter stress fiber
formation. However, the eGFP-Actin-C374A overexpressing cells mostly had an absence
of stress fibers. Quantitation of cells containing either strong, weak or no stress fibers
(Figure 4.7B) was then carried out. The eGFP-Actin expressing cells contained roughly
equal proportions of all three stress fiber forms; 30.68 ± 1.61% of cells had strong stress
fibers, 33.47 ± 1.49% of cells had weak stress fibers, and 35.85 ± 1.38% of cells had no
stress fibers. The eGFP-Actin-C374A expressing cells contained significantly fewer cells
with strong stress fibers, and a significantly greater number of cells with no stress fibers;
with only 6.96 ± 0.86% and 70.62 ± 5.56% respectively. eGFP-Actin-C257A and eGFPActin-C272A expressing cells were also quantitated, but neither showed significant
difference for any of the categories when compared to the eGFP-Actin wild type control.
This suggests cysteine 374 is important for actin polymerization and stress fiber
formation.
These findings were supported by the literature. Cysteine 374 in actin may be
involved in the formation of actin dimers, and post-translational modifications that
normally occur on cysteine 374 are associated with lower rates of polymerization and
weakening of actin filaments

21,22

. Therefore, the mechanism of action for TBE-31 on

actin polymerization, and possibly cell migration, could potentially be interrogated using
eGFP-Actin-C374A in a cell overexpression model.
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4.4.6 Transwell Cell Migration Assays
We previously demonstrated that TBE-31 interacts with actin and inhibits cell
migration. In brief, NIH3T3 cells were transfected with vectors encoding eGFP-Actin or
eGFP-Actin-C374A, and 50, 000 of these cells were seeded into Transwell inserts after
24h. The top chamber contained serum free medium, whereas the bottom chamber
contained either serum free medium, or medium supplemented with 10% FBS as a
chemoattractant. DMSO or TBE-31 (0.25 or 0.5 μM) was added to both upper and lower
chambers. The cells were given 18h to migrate before fixing the membrane, staining with
DAPI and mounting for immunofluorescence analysis (Figure 4.8A)
For each condition, the fraction of all cells that migrated through the insert was
first determined from the number of DAPI-stained nuclei (Figure 4.8B). For cells
expressing eGFP-Actin, the DMSO control treatment showed an average of 627.8 ± 52.8
cells that had migrated per field, whereas with the 0.25 µM or 0.5 μM TBE-31 treatment,
cell number decreased to 559.38 ± 59.9 and 322.8 ± 57.5 cells per field, respectively.
Similarly, the cells expressing eGFP-Actin-C374A treated with DMSO control, had an
average of 606.9 ± 65.0 cells per field, whereas the 0.25 µM or 0.5 µM TBE-31 treatment
again reduced the total number of cells that migrated through the insert to 511.7 ± 38.2
and 284.6 ± 44.5, respectively.
The total number of transfected cells was also determined by scoring GFPexpressing cells (Figure 4.8C). Interestingly, the proportion of cells expressing either
eGFP-Actin or eGFP-Actin-C374A was not affected by TBE-31 compared to cells not
expressing eGFP-labeled actin. Furthermore, cells expressing either form of actin
responded in a similar way to TBE-31 treatment. These results show that TBE-31 does
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Figure 4.8 Transwell cell migration with eGFP-Actin and eGFP-Actin-C374A
A) NIH3T3 cells were transfected with eGFP-Actin or eGFP-Actin-C374A. After 24h,
the cells were serum starved for 4h before seeding into the transwells. The top chamber
contained serum free media, while the bottom contained 10% serum. Either DMSO, or
TBE-31 (1mM) was added into both compartments. After 18h of cell migration, the
membranes were excised and prepared for immunoflouresence imaging. Images were
taken at 100x magnification.
B) Quantitation of the entire population of cells by counting the nuclei in the experiment
above. Errors bars represent the mean ± SEM. *P<0.05, **P<0.01 compared to the
DMSO control. (n=4)
C) Quantitation of the eGFP-Actin or eGFP-Actin-C374A population by counting cells
fluorescing green in the experiment above. Errors bars represent the mean ± SEM.. (n=4)
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inhibit cell migration as we have shown in the past with other techniques . However,
overexpressed actin, regardless of whether it can bind to TBE-31 or not, confers some
resistance towards TBE-31-dependent inhibition of migration.
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4.5 Discussion
In this study we demonstrated that iodoacetamide, a cysteine alkylating agent,
interferes with the ability of TBE-31 to interact with actin. Computational analysis
highlighted 4 cysteines as putative binding targets for TBE-31. Two approaches were
used to validate these potential binding targets, a mass spectrometry, and a mutagenesis
based approach. With the mass spectrometry approach, we were able to successfully
demonstrate that incubation of actin with TBE-31 was able to form a new mass
corresponding to the mass of actin and TBE-31 together. The absence of a second peak
corresponding to the mass of two TBE-31 molecules and actin, suggests only one
molecule of TBE-31 binds per molecule of actin. The same conditions were submitted for
tandem MS/MS to identify which cysteine TBE-31 is interacting with, but the results
were inconclusive due to a lack of coverage of peptide fragments containing Cys 374.
Thus, a mutagenesis approach was used instead to determine which cysteine TBE-31
interacts with. A pull-down analysis was used with a panel of cysteine to alanine
mutations, and the eGFP-Actin-C374A showed a significant reduction in pull-down by
biotin labeled TBE-31. Further analysis of this C374A mutant showed impaired
incorporation of this actin form into stress fibers, with the majority of cells containing
either weak or no eGFP-Actin-C374A stress fibers. This suggested that this actin mutant
would exhibit impaired incorporation into actin microfilaments. Transwell migration
assays were conducted and the number of cells migrating through the transwells was
significantly reduced by TBE-31. Taken together, these results suggest that TBE-31
interacts with actin through Cys 374 to inhibit actin polymerization and this may be a
mechanism wherein TBE-31 utilizes to inhibit cell migration.
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Our findings showing impaired incorporation of eGFP-Actin-C374A into stress
fibers is consistent with the literature. Cys 374 has been reported to have an important
role in establishing intermonomer contacts and may stabilize the interstrand relation in
the actin filament

23,24

. Furthermore, redox modification of Cys 374 has also been linked

to intramolecular disulfide bond formation, decreased polymerization rates, increased
critical concentrations and filament weakening

21

. Indeed, S-(cysteine-374)glutathionyl

actin was found to form filaments of low mechanical stability

22

. An analysis of

tetramethylrhodamine(TMR)-labeled actin at Cys 374 showed TMR-actin polymerized in
very short filaments, which were easily destabilized by ATP hydrolysis. The critical
concentration for polymerization of TMR-actin were found to be an order of magnitude
higher than that of unlabeled actin. In addition the interaction of actin with a number of
actin regulating proteins was profoundly altered by TMR labeling

25

. Interestingly, the

modification of Cys 374 has been implicated in the regulation of the actin cytoskeleton
reorganization during cell adhesion and cell spreading 26, which are important processes
in cell migration

1-3

. Therefore the notion of TBE-31 interacting with actin through Cys

374 to impair actin polymerization and inhibit cell migration is consistent with the
literature.
Interestingly, the overexpression of eGFP-Actin or eGFP-Actin-C374A reduced
the inhibitory effects of TBE-31 on cell migration, even though only the wild-type eGFPActin should associate efficiently with TBE-31. In my previous studies (Chapters 2 and
3) we showed that TBE-31 has many putative binding targets 12. We have examined the
effects of TBE-31 on the microtubule network, vesicle trafficking, and front-rear polarity,
and demonstrated that TBE-31 disrupts all of these

27

. Perhaps cell migration cannot be
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fully recovered from this multi-targeted drug by simply overexpressing eGFP-ActinC374A, because it is inhibiting cell migration through multiple proteins. However, since
actin microfilaments are essential for cell migration, and modification of actin at Cys 374
negatively effects actin polymerization, further studies on the effects of TBE-31 on the
actin cytoskeleton are warranted. Our previous studies (Chapter 2) have shown that stress
fiber formation in the presence of TBE-31 results in short filaments, which is consistent
with the analysis of TMR-actin

25

. It may be interesting to examine the stability of the

TBE-31 modified actin filaments by using electron microscopy or measuring ATP
hydrolysis by the filament as done previously by Conchaudron et al 25.
A purified source of actin, and actin containing the cysteine to alanine mutations
will open many avenues of experiments. We previously sought to generate a purified
source of GST-actin and the cysteine mutants. We successfully excised the actin
sequence from our eGFP vectors, and inserted them into a pGEX-4T-1 GST vector. They
were then successfully expressed in BL21 competent cells, lysed and the GST tagged
protein was precipitated with glutathione beads. However, despite using multiple
approaches the elution of the protein from the beads was not successful. The approaches
included using thrombin to cleave the protein from the GST, gradients of Triton X-100,
guanidine and urea—strong denaturing agents, glutathione, and high salt concentrations.
Only by using a combination of the above was a small amount of protein eluted and its
activity seemed compromised—most likely due to improper refolding after using the
denaturing agents. Future attempts at purifying actin and the cysteine mutants may be
more fruitful by using a polyhistidine-tag instead of a GST-tag, and a baculovirus/SF9
cell expression system. Once the purified protein is obtained, in vitro actin
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polymerization assays can be performed to perhaps demonstrate a dampened effect by
TBE-31 in the cysteine mutants. In addition, mass spectrometry analysis can be used with
the mutants to show changes (or lack of) in the whole protein mass shift, or fragment
labeling.
Tandem MS/MS was not conclusive in determining which cysteine on actin TBE-31
interacts with. The relatively low amount of TBE-31 labeled actin, compared to unlabeled
actin in the samples, was especially problematic considering the poor coverage of Cys
374. We attempted to address this by analyzing actin cleaved with chymotrypsin, or
trypsin. Future experiments using other endoproteinases (for e.g., AspN) may generate
peptides that yield better coverage. In addition, a bottom-up approach for analysis has
been proposed where a synthesized N-terminal fragment containing Cys 374 could be
labeled with TBE-31 and analyzed by Mass Spectroscopy. This can be used to test if the
fragment and TBE-31 can withstand the ionization energy of MS/MS and be amenable
for analysis.
Overall, this study provides novel insight on the underlying mechanisms by which
TBE-31 utilizes to inhibit cell migration. It was demonstrated that TBE-31 interacts with
actin through Cys 374, which is necessary for efficient actin polymerization and stress
fiber formation. Thus making TBE-31 an attractive candidate for targeting the actin
cytoskeleton and tumour cell migration in metastasis.
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Chapter 5

5.1 Summary
Cancer arises from cells that have undergone multiple genetic mutations that lead
to the loss of normal cellular behaviour

1,2

. These mutations initially result in

uncontrolled growth and proliferation. As the malignant cells continue to gain genetic
mutations, some cells will gain the ability to migrate and invade adjacent tissue, and
disseminate to distant organs where they may establish new tumour colonies. These
colonies are known as metastases, and are responsible for over 90% of human cancer
related deaths

3-6

. Cell migration is a key process in promoting metastasis, and to date

effective drugs targeting metastasis are lacking 6-10.
Synthetic oleanolic acid agents have received notable attention in recent years for
their multiple anti-tumourigenic effects, which include inducing apoptosis, reducing
inflammation, and inhibiting proliferation of tumour cells. Studies in our laboratory have
also demonstrated that the specific synthetic oleanolic acid derivatives, CDDO-Im and
CDDO-Me, target the cytoskeleton and inhibit cell migration

11,12

. More recently,

medicinal chemists have synthesized a class of three ring compounds known as TBEs.
They resemble the CDDO compounds and contain the same active regions responsible
for their potency. TBE-31 was found to be particularly potent in anti-inflammatory
assays, and many studies have outlined the effects of TBE-31 on the KEAP1/Nrf2
pathway. However their effects on cell migration were entirely unknown. Given their
structural similarities to the CDDO compounds, I hypothesized that TBE-31 will inhibit
cell migration by targeting components of the cytoskeleton. The three specific aims I
designed to address this hypothesis were to:
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1) Characterize the effect(s) of TBE-31 on the actin cytoskeleton and cell
migration.
2) Characterize the effect(s) of TBE-31 on the structure and dynamics of the
microtubule network and cell migration.
3) Determine how TBE-31 interacts with actin.

Data from experiments designed to address aims 1, 2, and 3 are presented in
chapters 2, 3, and 4 respectively, and are briefly summarized below.

Arp2/3 is involved in the actin polymerization and the formation of the
lamellipodia in cell migration

1,2,13

. CDDO-Im and CDDO-Me have been shown to

interact with Arp3, inhibit Arp2/3 activity and localization to the leading edge

12

. In

chapter 2, I determined that, unlike CDDO-Im or CDDO-Me, TBE-31 does not alter
Arp3 localization to the leading edge. Using TBE-56 (biotin labeled TBE-31), I identified
a number of putative protein binding partners. Of the identified proteins, actin was of
particular interest as it is provides the force for generating cellular protrusions and
establishing lamellipodia, key events for cell migration. The interaction between TBE-31
and actin was further validated and the results obtained suggested TBE-31 is able to
associate with actin. I then demonstrated that TBE-31 is able to inhibit actin
polymerization using an in vitro assay and inhibit actin stress fiber formation in NIH 3T3
fibroblasts, which is entirely unique effect from CDDO-Im or CDDO-Me. These findings
were then applied to the model of epithelial-to-mesenchymal transition (EMT), a
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precursor event to cancer metastasis. TGFβ was used to induce EMT in A549 lung cancer
cells, and the rearrangement of cortical actin to actin stress fibers was inhibited by TBE31. Lastly I demonstrated using scratch assays, and single cells, that TBE-31 is effective
in inhibiting H1299 lung cancer cell, and NIH 3T3 cell migration for the first time.
In chapter 3, I identified tubulin to bind to TBE-31. However, unlike actin, TBE31 was not found to inhibit the polymerization of tubulin, but instead it was found that
TBE-31 alters the organization of the microtubule network and its dynamics.
Microtubule-dependent processes were then investigated and TBE-31 was shown to
disrupt microtubule-dependent trafficking. I then demonstrated that TBE-31 alters frontrear polarity in migrating cells, in a manner distinct from CDDO-Im. TBE-31 treated
cells were observed to form multiple protrusions of active Rac1, whereas CDDO-Im
reduces active Rac1 localization at the membrane. Since a single dominant leading edge
is necessary for efficient directed cell migration, I then demonstrated that TBE-31
inhibited cell migration of Rat2 fibroblasts.
In chapter 4, the focus was on better understanding the biochemical interaction
between actin and TBE-31 to determine the mechanism(s) in which TBE-31 utilizes to
inhibit actin polymerization and cell migration. Previous work has suggested that TBE-31
may undergo Michael addition with nucleophilic targets containing reactive sulfhydryl
groups (thiols)

14,15

. However, no previous work has identified any specific cysteines on

any proteins. By blocking the thiol groups on actin with a cysteine alkylating agent, the
interaction between TBE-31 and actin was inhibited. Thus suggesting TBE-31 interacts
with actin through cysteine thiol groups. This finding was supported by data from
computational simulations. Furthermore, cysteine 374 was identified as a potential
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candidate. Using mass spectrometry, it was determined that one molecule of TBE-31
interacts with one molecule of actin. LC/MS-MS was used to try to determine the exact
cysteine(s) TBE-31 interacts with, however due to limitations of the technique this was
not possible. Instead a pull-down approach was utilized with wild-type or mutated GFPactin. I determined that TBE-31 interacts with actin through cysteine 374, marking this as
the first ever identified target at the amino acid level. Characterization of the GFP-actinC374A, demonstrated that cysteine 374 is necessary for efficient actin stress fiber
formation. This suggests it may important for actin polymerization, which is supported by
past research by others 16-19. The final experiment of this chapter attempted to interrogate
the exact mechanism of action for TBE-31 on cell migration by overexpressing GFPactin-C374A. Although these results confirmed TBE-31 inhibits cell migration using a
third technique, they were not able to clearly demonstrate a recovery effect by
overexpression, as the control GFP-actin reduced the effects of TBE-31 as well.
However, the notion of TBE-31 interacting with actin through cysteine 374 to impair
actin polymerization and inhibit cell migration is consistent with other studies on cysteine
374 modification on actin 20,21.

5.2 Limitations and Future Experiments
In this thesis, I demonstrated that TBE-31 interacts with the thiol groups of
reactive cysteines, thus TBE-31 is a multi-targeting drug. Indeed, in chapter 2 and 3, a
number of putative binding targets for TBE-31 were identified. Due to the multi-targeted
nature of this drug, it was difficult to attribute specific phenotypic changes to specific
targets. For instance, since the microtubule network and the actin cytoskeleton are
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intimately linked, it is difficult to attribute the mislocalization of the polarity proteins
specifically to the microtubule network alone. Future studies examining the effects of
TBE-31 on other proteins, and other processes should keep this caveat in mind. For this
reason, it was helpful to study the proteins in isolation in in vitro polymerization assays.
Indeed, this approach was useful for the heavily mechanistic nature of my studies, and
was valuable for narrowing down the mechanisms by which TBE-31 inhibits cell
migration. However, it is important to note and remember for future studies, that these
assays may not fully reflect what happens in vivo. In the cell, the cytoskeleton is tightly
regulated in time and space by a large number of signaling, scaffolding and binding
proteins

22

. One of the limitations encountered in this study was the inability to silence

the expression of actin or tubulin as they are fundamental to other processes outside of
cell migration, such as cell division and providing structure to the cell

22

. In order to

recapitulate the effects of TBE-31 on these proteins in cell migration, it may be necessary
to silence their regulatory proteins instead. For instance, formin and profilin which
enhance general actin polymerization rates 23, can be silenced in lieu of actin. Similarly,
another limitation of this study was the inability to properly overexpress GFP-actinC374A. Due to the nature of the mutant, only low-to-medium levels of expression were
tolerated before the actin cytoskeleton was compromised. This may explain why a
recovery effect was not observed when GFP-actin-C374A was overexpressed in the
transwell migration assays carried out in chapter 5. Future studies may need to resort to
using an in vitro polymerization assays with a purified source of actin-C374A instead.
The C374A mutant would be expected to have lower intrinsic rates of polymerization, but
since TBE-31 does not interact with the mutant, it is expected that this rate of
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polymerization will be unaffected by TBE-31. Thus determining the specific mechanism
in which TBE-31 inhibits actin polymerization.
A major focus of my thesis was on the effects of TBE-31 on cell migration.
Multiple approaches were used to assess this, including scratch assays, single cell
migration, and transwell migration assays. It is important to identify the caveats and
limitations of each technique as used in these studies. Scratch assays may be influenced
by rates of cell proliferation. The studies addressed this by tracking single cells in sub
confluent migration assays. However a caveat of this technique is that it is dependent on
the cell type’s inherent predilection for exploring the environment, since no stimulus is
present to induce cell migration. Transwell assays permit chemotaxis and is an excellent
model for directed cell migration, but because the cells are usually fixed and stained in
order to be quantified, they are endpoint assays. They cannot provide kinetic data as
easily as the scratch and subconfluent cell migration assays do. Therefore this assay
cannot distinguish between cells that have migrated a great distance versus a short
distance, and can only discern between cells that have or have not migrated through the
pores of the membrane. Therefore, the studies in this thesis utilized all three of these
techniques to complement one another and minimize the above limitations to generate
robust data to support the hypothesis.
Complementary future experiments may can include the use of the µ-Slide
Chemotaxis (ibidi) system. In brief, two reservoirs are connected by a narrow observation
area. The cells under investigation are seeded into the observation area, one reservoir is
filled with regular media, while the other reservoir is filled with media containing a
chemoattractant, which results in a gradient of the chemoattractant in the observation
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area. This technique would allow for full observation over the course of the experiment—
which would allow the collection of kinetic data—would not be as prone to influence
from cell division, and still benefit from inducing directed cell migration with a
chemotactic gradient.
It is also important to note that cell motility during the metastasis cascades
includes cell migration and cell invasion. Although the two processes share similarities, it
is important to note differences. During invasion, instead of lamellipodia, invadopodia
form to mediate the migration and degradation of the extracellular matrix with matrix
metalloproteases (MMP) 24. The invadopodia is comprised of an actin-filament rich core
and a protein complex composed of integrins and integrin-associated proteins like
vinculin, talin and paxillin

24

. In addition, scaffolding proteins such as Tks5 have also

been identified to be specific to invadopodia 25. Therefore, cell invasion is dependent on
migration, but may require different mechanics 24,26. My studies have demonstrated TBE31 as an effective inhibitor of cell migration, and warrant future experiments to include
complementary models for cell invasion. The transwell migration assays from this thesis
can easily be adapted to study invasion. A standard technique in the field is to coat the
transwell inserts with Matrigel (Corning)

27

, a solubilized basement membrane

preparation, before seeding cell in the top chamber. In addition, another common
technique is to seed the cells into a bed of Matrigel to study three dimensional cell
culturing

28

. Invasive cell lines will form protrusions to invade into the surrounding

Matrigel. Lastly, a mixture of Matrigel and cells can be seeded into the µ-Slide
Chemotaxis system outlined above to monitor chemotaxis directed cell invasion over
time. Since TBE-31 targets the actin and microtubule cytoskeleton—components that are
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also fundamental to cell invasion—it is expected that TBE-31 would inhibit invasion as
well.
The in vitro cell migration techniques used in this thesis, and the in vitro cell
migration and invasion assays proposed for future experiments above are valuable tools
for initial studies and characterizing the effects of TBE-31. However, they may not be
fully reflective of cell migration and invasion in vivo. For instance, cells utilize a greater
range of protrusive structures such as blebs, lobopodia and pseudopods to squeeze
through the extracellular matrix in vivo instead of forming only lamellipodia

29,30

. The

varying substratum of the extracellular matrix may provide multiple haptotactic cues, and
multiple chemotactic agents can originate from various directions, thus further
complicating the establishment of polarity

30

. The promising results from my thesis

justify the extension of my findings into animal models for future experiments. More
specifically, the cancer cells can be transplanted into immunocompromised mice. A
group of mice would receive intraperitoneal injections of TBE-31 suspended in saline
while another group will receive equal injections of DMSO suspended in saline. After a
period of time, organs can be harvested and examined for surface nodules, or subjected to
histology for examination of metastatic burden. Studies such as these would examine
metastasis as a whole, and be a more specific indication of how effective TBE-31 inhibits
cell migration and invasion to reduce metastasis. Based on what has been demonstrated in
this thesis, it would be expected that TBE-31 would inhibit tumour cell migration and
invasion to reduce metastasis burden to distant organs.
During the study of TBE-31 on the cytoskeleton and cell migration, it was
interesting to observe how TBE-31 has effects on the cytoskeleton unique from CDDO-
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Im and CDDO-Me. In chapters 2 and 4, I demonstrated that TBE-31 binds to actin to
inhibit polymerization, while other studies have shown CDDO-Im and CDDO-Me target
Arp2/3 to inhibit the induction of branched actin polymerization. Interestingly, the
general effect of inhibiting cell migration was observed with all three. Perhaps by
targeting actin polymerization in two different manners critical for cell migration, better
specificity and greater potency can be achieved with a combination of these two class of
compounds. Future studies may benefit from examining this possible synergistic effect.

5.3 Significance and Conclusion
Metastasis accounts for over 90% of cancer related deaths. Significant progress
has been made in understanding metastasis, however there is still a severe lack of
therapies targeting the numerous processes involved

8-10

. Most of the available therapies

primarily focus on cancer growth 9. One potential approach is to target tumour cell
motility as a strategy against tumour cell migration, invasion, and metastasis 31,32.
The synthetic triterpenoids and tricyclic compounds have gained attention in the
recent years for their anti-inflammatory properties. Previous studies have shown the
synthetic oleanolic acid derivatives have anti-migratory properties however the effects of
TBE-31 on cell migration were completely unknown until now. My work has gleaned
insight on how TBE-31 modulates various aspects of the cytoskeleton and polarity, in a
fashion entirely unique from CDDO-Im or CDDO-Me. More specifically I demonstrated
for the first time that TBE-31 targets the actin cytoskeleton, microtubule network, and
polarity proteins, and inhibits tumour cell migration (Figure 5.1). This makes TBE-31 an
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attractive candidate for targeting tumour cell motility in cancer metastasis, and warrants
further investigation. In addition, this knowledge will be important for developing more
efficacious and specific tricyclic compounds and synthetic triterpenoids for targeting
cancer metastasis.
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Figure 5.1 The effects of the syntehtic oleanane triterpenoids and tricyclic
compounds on cell migration
A) A summary of previous findings on the effects of CDDO-Im on cell migration. Top,
CDDO-Im was found to alter microtubule dynamics by disrupting the microtubule
capping protein, Clip-170, disrupt microtubule dynamics and organization, and cause a
loss of polarity proteins to the leading edge. Bottom, CDDO-Im was found to inhibit
Arp2/3-dependent branched actin polymerization at leading edge. Note filopodia
unaffected as its formation is independent of Arp2/3.
B) A summary of the effects of TBE-31 on cell migration found in this thesis. Top, I
determined TBE-31 directly binds to tubulin and interferes with microtubule dynamics
and the polarity proteins Rac1, IQGAP and Tiam1 were found to localize to multiple
conflicting locations around the cell periphery, resulting in the loss of a single dominant
protrusion. Bottom, I determined TBE-31 binds to cysteine 374 of actin—a critical
cysteine for filamentous actin stability—and inhibit actin polymerization. All of which I
believe contribute to inhibiting efficient cell migration.
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